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Abstract 
CZ48, a novel C20-propionate ester of camptothecin (CPT), shows promising antitumor 
activity as a topoisomerase I (Topo-) inhibitor. Compeling evidence indicates that CZ48 
is more effective and less toxic than other anticancer agents, many of which are in 
clinical use such as Adriamycin, Alkeran, and 5-FU. However, poor solubility and the 
effective delivery challenges have been the obstacles for application of the drug to 
patients.  
Interestingly, many studies have shown that a prolonged exposure of Topo- inhibitors 
with low concentrations is more efficacious in cancer treatment compared with a short 
term exposure with high concentrations, though the exact mechanism remains unknown. 
In an attempt to accelerate the development process and promote the clinical trials of 
CZ48, we hypothesized that CZ48 can be formulated into nanosuspensions which 
deliver CZ48 in a sustained fashion. Sustained delivery of CZ48 could provide a 
prolonged exposure of CPT, the actual active compound, thus leading to an enhanced 
antitumor activity. The success in formulating the CZ48 nanosuspension will overcome 
the limitaions of the drug (e.g., the poor solubility and short half-life) and push it into the 
first line option in cancer chemotherapy based on the achieved outstanding efficacy and 
low toxicity. Further, the passive targeting property of nanosuspension may provide 
additional merits for CZ48 chemotherapy.  
Toward the goal, our specific aims are: (1) to prepare by wet media milling method and 
characterize CZ48 nanosuspensions. We aim to obtain two types of nanosuspensions 
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that differ considerably in the particle size. In vitro release study will be carried out by 
dialysis bag diffusion technique; (2) to determine the pharmacokinetics and organ 
distribution of CZ48 (and CPT) from CZ48 nanosuspensions in Sprague-Dawley (SD) rat 
and Swiss nude mouse models. The pharmacokinetic profiles and biodistribution 
patterns of CZ48 (and CPT) will be established by administering CZ48 as a 
nanosuspension following intravenous (i.v.) administration; (3) to determine the efficacy 
of CZ48 nanosuspension in tumor-bearing athymic mouse model. The lead formulation 
with the most favorable pharmacokinetic properties will be selected to validate the 
antitumor activity in a well-established tumor-bearing mouse model. The efficacy will be 
mainly measured by the suppression of tumor growth and the survival rate.  
Two types of CZ48 nanosuspensions with particle sizes of 200 nm (NS-S) and 600 nm 
(NS-L), respectively, were successfully formulated and extensively characterized. The in 
vitro release study showed a sustained release of CZ48 from nanosuspensions 
compared with the release from cosolvent (reference). Pharmacokinetic studies in SD 
rats and Swiss nude mice demonstrated that compared to CZ48 cosolvent, CZ48 
nanosuspensions increased the systemic exposure of CZ48 and prolonged the blood 
circulation of CPT. Moreover, the half-life was much longer and AUC was much larger of 
CPT from NS-S than those of NS-L. In tested organs, CZ48 nanosuspensions showed 
the largest value of CZ48 AUC in liver, spleen and lung after the i.v. administration. For 
both nanosuspensions, a prolonged half-life of CPT was observed in all the test organs 
compared to those from cosolvent. CZ48-loaded nanosuspension (NS-S) exhibited 
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significant tumor inhibitory effect with a higher tolerable dose, and an improved survival 
rate compared to CZ48 cosolvent.  
In conclusion, this study for the first time demonstrated that nanosuspension was a 
viable pharmaceutical carrier that delivered CZ48 in a sustained manner and achieved 
significant tumor growth suppression at a higher tolerable dose. The study provides a 
formulation strategy that has a great potential to overcome the delivery barriers for many 
other anticancer drugs. We anticipate that CZ48 nanosuspention will be a lead candidate 
for the clinical trials on CZ48 in the near future. 
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Chapter 1 Review of the Literature 
CZ48 (Figure 1a), a novel C20-propionate ester of camptothecin (CPT) (Figure 1b), was 
synthesized by the scientists at the CHRISTUS Stehlin Foundation for Cancer Research 
(Houston, TX). The drug shows promising antitumor activity as a DNA topoisomerase- 
(Topo-) inhibitor. CZ48 is converted to CPT (the actual active moiety) in vivo via the 
esterases (Figure 2). In this regard, CZ48 is considered as a prodrug of CPT.  
CZ48 is a novel and potent anticancer agent, currently in Phase-I clinical trials. In 
addition, CZ48 has the merit of being a CPT ester with a minimal toxicity to animals. 
Body weight losses, an indicator of toxicity, in nude mice were not observed with oral 
doses as high as 200 mg/kg (Cao Z et al, 2000). For this reason, CZ48 can be viewed 
as a low toxicity prodrug reservoir of CPT.  
 18 
 
 
Figure 1 Chemical Structures of CZ48 and Analogs: a. CZ48; b. CPT; c. CZ44 
 19 
 
 
Figure 2 Bio-transformation of CZ48 to CPT 
CEs 
 20 
 
1.1. CPT 
1.1.1. Discovery of CPT 
In the 1950s, CPT extracts from the wood, leaves, bark and fruit of Camptotheca 
acuminata were found to have anti-tumor effects. In the early 1960s, the National 
Cancer Institute (NCI) Chemotherapy Program showed that CPT had promising anti-
neoplastic activity against murine leukemia tumor L1210 and rat walker carcinoma cell 
lines (Wall ME et al., 1966). Strong antitumor properties were also observed in other 
different experimental systems (Gottlieb JA et al., 1970; Muggia FM et al., 1972). 
In the 1960s, Due to the limited water solubility of CPT itself, CPT was entered into 
clinical trial as a water soluble sodium salt. However, it exhibited unpredictable and 
severe toxicity such as hemorrhagic cystitis, severe diarrhea, thrombocytopenia, and 
neutropenia which have inhibited the clinical application of CPT (Gottlieb JA and Luce 
JK, 1972; Moertel CG et al., 1972; Muggia FM et al., 1972).  As a result, the clinical 
development of CPT sodium was halted in the 1970s. 
1.1.2. New Interests of CPT 
Despite clinical withdrawal of CPT, researchers continued conducting laboratory studies 
on the drug for the following 20 years. In early 1980s, two major findings renewed the 
clinical interest in this agent.  
 21 
 
The first was that the intact lactone ring is an essential structure for cytotoxicity of CPT 
and its analogues (Wall ME and Wani MC, 1977). The intact lactone ring was also 
critical for their in vivo antitumor activity (Schultz AG, 1973; Wani MC, et al., 1980; 
Hertzberg RP, et al., 1989). The structure of CPT with a closed E-ring is shown in Figure 
1b. Unfortunately this lactone ring is susceptible to spontaneous reversible hydrolysis in 
vivo at the physiological pH of 7.4 and readily opens to yield the opened-ring carboxylate 
form (Figure 3) (Fassberg J and Stella VJ, 1992). This reaction is reversible, pH-
dependent and influenced by the presence of specific binding proteins such as human 
serum albumin (HSA) in the biological matrix. In human patients, the ratio of CPT-
lactone form and CPT-carboxylate form is 1:9, because 1). At physiological pH, the 
equilibrium favors the CPT-carboxylate form over the lactone form of CPT (Fassberg J 
and Stella VJ, 1992); 2). The carboxylate form preferentially binds to serum albumin, 
which results in a more rapid ring opening in CPT circulation. However, the activity of 
CPT-carboxylate form is about 10-times less potent than CPT lactone form (Hertzberg, 
1989). Therefore, the development of CPT analogues aimed at increasing the aqueous 
solubility of this lipophilic agent as well as improving the lactone stability in vivo for 
optimum therapeutic efficacy.  
The second major finding was the elucidation of the mechanism of the action of CPT as 
an inhibitor of the mammalian nuclear enzyme, DNA topoisomerase- (Topo-) (Hsiang 
YH and Liu LF, 1988). Interestingly, Topo- is overexpressed in certain tumor types 
including cervix (McLeod HL et al., 1994) and colon (Giovanella BC et al., 1989) tumors 
as significantly increased concentrations of this enzyme, compared to that in normal 
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colonic mucosa, were found in advanced stages of human colon adenocarcinoma and in 
xenografts of colon cancer carried by immunodeficient mice. CPT inhibits Topo- by 
blocking the rejoining step of the cleavage/religation reaction of Topo-, resulting in 
accumulation of a covalent reaction intermediate, cleavable complex (Figure 4). It results 
in interferences with the relegation step, leading to double stranded DNA breaks and, 
ultimately, to cell death in the S-phase of cell cycle (Hsiang YH et al., 1985, 1989). In 
this way, CPTs are S-phase cell cycle specific agents, in which optimal therapeutic 
efficacy generally requires prolonged exposure of the tumor to drug concentrations 
exceeding a minimum threshold.  
These two findings have revived the interest in CPT and led to the development of more 
active CPT analogues. Development efforts aimed at increasing the aqueous solubility of 
this lipophilic agent as well as improving the lactone stability in vivo for optimum 
therapeutic efficacy. 
1.1.3. CPT Analogues 
With the clinical interest in CPT revived after the discoveries of its mechanism of action 
and the importance of the lactone ring, new analogues were being developed. There are 
several CPT analogues in different stages of development. Two water-soluble CPT 
analogues Topotecan (Hycamtin®) and Irinotecan (Camptosar®) have been approved 
by FDA for clinical use. Topotecan is indicated as a second-line therapy for advanced 
ovarian cancer, small cell lung cancer, and cervical cancer. Irinotecan is indicated as 
first line therapy in combination with fluorouracil for the treatment of colorectal cancer. 
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However, the response rates of clinical anticancer activity of these two agents are 
modest, 12-50% depending on the type of cancer being treated (Takimoto CH et al., 
1998).  
Previous studies have suggested that prolonged exposure to low concentrations of CPT 
lactone is more relevant than short-term exposure to high concentrations (Gerrits CJ et 
al., 1997). For Topotecan, as early as 45 minutes after the start of a 30 minute infusion, 
the carboxylate form has already exceeded the lactone form level in plasma (Grochow 
LB et al., 1992). Studies have suggested that the open-ring carboxylate may contribute 
to myelosuppression. At pH 6, more than 80% of the total Topotecan is in the lactone 
form, but at physiologic pH, Topotecan is rapidly hydrolyzed to the carboxylate form 
(Dennis MJ et al., 1997). Irinotecan is a prodrug of the active SN-38, but only 2 ~ 4% of 
irinotecan is converted to the active drug (Rothenberg ML et al., 1993). All these make a 
new anticancer drug more urgent. 
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Figure 3 Equilibrium between Lactone and Carboxylate Forms of CPT 
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Figure 4 Mechanism of CPT (Topo- inhibitor) Action-Stabilization of the DNA-
Topo- Cleavable Complex in the Presence of Ongoing DNA 
Replication Generates Cytotoxic DNA Damage 
CPT 
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1.2. CZ48 
1.2.1. Discovery of CZ48 
Recognizing the potential promise and apparent limitations of the available CPT 
analogues, various alkyl esters of CPT were synthesized by scientists at Christian 
Stehlin Foundation for Cancer Research (Houston, TX) to circumvent problems of rapid 
lactone hydrolysis (Cao Z et al., 1998). Among these CPT esters, CZ48, camptothecin-
20(S)-O-propionate hydrate, is the most effective candidate in inhibiting growth and 
inducing apoptosis in HL-60 and U-937 cells (Cao Z et al., 2000). Therefore, CZ48 was 
considered for further study. 
1.2.2. Merits of CZ48 
The lactone stability of CZ48 is significantly improved after the substitution of a bulky 
acyl group on the E-ring to interfere with albumin binding. Incubated in phosphate 
buffered saline solution (PBS) with the presence of HSA at 37 C for 4 h, CZ48 is stable 
and there is no detectable hydrolysis to its carboxylate form (Liehr JG et al., 2000). The 
bulky ester chain in the vicinity of the lactone moiety interferes with albumin binding and 
thus inhibits the conversion of the active lactone form of CZ48 to inactive carboxylate 
form. Moreover, the 20-OH group in conventional CPTs interacts with the carboxylate 
oxygen by H-bonding and facilitates ring opening. Acylation of this hydroxyl group in 
CZ48 diminishes H-bonding interactions and results in a slower rate of lactone 
hydrolysis. 
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Besides the improved lactone stability, CZ48 has shown anticancer activity against 
tumor cells in culture. It also has anticancer activity against human tumor xenografts in 
nude mice with an exceptional lack of toxicity. CZ48 acts as a prodrug and exerts the 
antitumor activity by carboxylesterases (CEs) mediated hydrolysis to the active 
metabolite CPT in vivo (Liehr JG et al., 2000). In vitro study of CZ48 metabolism has 
showed that among blood and CE-containing tissues such as liver, spleen, lung and 
kidney, the liver has the highest metabolic capacity to convert CZ48 to CPT (Satoh T 
and Hosokawa M, 1998) instead of in blood, consistent with the fact that the highest CEs 
activity is in the liver. 
CZ48 acts as a prodrug reservoir with a low toxicity (Cao Z et al., 2000). CPT converted 
from CZ48 dosing persists longer in blood circulation than that from CPT dosing. The 
prolonged persistence may offer an advantage of continuous exposure of CPT at a 
desired concentration for an extended period of time. As a result, CPT is continuously 
generated and entering the susceptible S-phase of the cell cycle, which leads to an 
enhanced therapeutic efficacy of CZ48. 
In a word, CZ48 is a promising novel Topo- inhibitor in the class of CPT anologes, 
combining the properties of improved lactone stability, reserved antitumor activity and 
low toxicity. Further studies including administration route and formulation of CZ48 are 
needed in order to provide guidelines for effective dosing of this agent. 
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1.2.3. Limitations of CZ48 
The poor solubility of CZ48 is a big challenge to administer the drug. A cosolvent 
formulation, containing Dimethyl sulfoxide (DMSO), polyethylene glycol 400 (PEG400), 
Ethonal, was developed by Xiaohui Li in 2004 to study the pharmacokinetics of CZ48. It 
also can be given by i.v. injection. Due to the high content of organic solvent, the 
injection volume was limited. In addition, multiple doses can not be given because of the 
severe tissue damage. In addition, Topo- inhibitors are S-phase cell-cycle specific and 
in vitro and in vivo studies have suggested that prolonged exposure to low 
concentrations might indeed be more relevant for efficacy than short-term exposure to 
high concentrations (Gerrits CJ et al, 1997). Therefore, developing a sustained release 
nanoformulation for CZ48 could overcome the administration challenge, provide a 
prolonged exposure of CPT at the site and the passive targeting of nanoformulation to 
reticuloendothelial system (RES) rich organs might have additional merits for the CZ48 
chemotherapy. 
1.3. Nanoformulations 
Nanocarriers loaded with chemotherapy drugs have become increasingly attractive to 
researchers because of the stabilization of nanoparticles and of their capability in uptake 
by and release from monocytes/macrophages.  
Nanoformulations refer to various drug delivery systems wherein the particle size of drug 
is in a nano range and can be given by various routes of administration, such as oral, 
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parenteral, and pulmonary pathways. These formulations have been widely used to 
deliver drugs in a sustained manner and to modulate the drug distribution pattern among 
tissues. The commonly used nanoformulations include lipospme, microsphere, 
microemulsion, nanosuspension and so on. 
1.3.1. Liposome 
Liposomes are spherical vesicles consisting of one or more phospholipid bilayer 
surrounding an aqueous core. The diameter of the liposomes varies from 0.02 ~ 10 μm 
(Drulis-Kawa Z and Dorotkiewicz-Jach A, 2010). The vesicles are built by the amphiphilic 
phospholipids. The polar head groups of the phospholipids form the interface to the 
aqueous media. The lipophilic agents are incorporated into the bilayer of the membrane 
while the hydrophilic agents are located within the water phase inside the vesicles 
(Korting HC and Schäfer-Korting M, 2010). The use of liposomes as a drug delivery 
system can improve the pharmacological properties of the traditional chemotherapeutics 
by altering drug pharmacokinetics and biodistribution (Allen TM and Cullis PR, 2004; 
Cukierman E and Khan DR, 2010).  
1.3.2. Microsphere 
Polymeric microspheres delivery system is one of the sustained-release systems that 
can accommodate a variety of drugs including small molecules proteins and nucleic 
acids. It can be easily injected in the site of action, for example brain tissue, if they have 
a proper size. Biocompatibility can be achieved by the use of natural polymers such as 
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cellulose, chitin, and chitosan or by the employment of polymers made from naturally 
occurring monomers such as lactic and glycolic acids. 
1.3.3. Microemulsion 
Microemulsions are drug delivery systems that have a considerable potential to act as 
drug delivery vehicles by incorporating a wide range of drug molecules. They are defined 
as clear, thermodynamically stable, isotropic mixtures of oil, water and surfactant and 
frequently in combination with a co-surfactant (Lawrence MJ and Rees GD., 2000). The 
droplet diameter is usually within the range of 10 ~ 100 nm and they form spontaneously 
by simple mixing of the various components (auto emulsification) (Vandamme TF, 2002). 
Microemulsions offer an interesting and potentially quite powerful alternative carrier 
system for drug delivery because of their high solubilization capacity, transparency, 
thermodynamic stability, ease of preparation, and high diffusion and absorption rates 
when compared to solvent without the surfactant system.  
1.3.4. Nanosuspension 
Nanosuspension formulations are carrier-free colloidal drug delivery systems for water-
insoluble drugs. It contains a pure drug nanoparticles and a minimum amount of surface 
active agents required for stabilization of the suspended drug particles in the aqueous 
medium (Gao L et al., 2007). Nanosuspensions have revealed their success to solve the 
problems associated with the delivery of the drugs with poor solubility in water or/and in 
organic solvent. As nanosuspension is stabilized by the minimum amount of surfactants 
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and the drugs remain in a solid state, the formulation has low toxicity, higher mass per 
volume loading, and higher physiochemical stability compared to the drug solution (Keck 
CM and Müller RH, 2006). The intravenous (i.v.) administration of nanosuspensions 
results in various pharmacokinetic profiles depending on its physical characteristics. For 
example, the pharmacokinetic profile and tissue distribution of a fast dissolving 
nanosuspension will be similar to that of the solution upon injection (Xiong R, et al., 
2008). On the other hand, if the nanosuspension particles had a slow dissolution profile, 
there will be a high possibility to be captured by the macrophages of the mononuclear 
phagocytic system (MPS), primarily by Kupffer cells in the liver, spleen and lungs in a 
process known as phagocytosis (Xiong R et al., 2008; Gao L et al., 2007) . Phagocytosis 
is triggered by the adsorption of certain plasma proteins (opsonins) on the surface of the 
foreign particles. Some studies showed that nanoparticles coated with polysorbate 80 
(T-80) on the surface could anchor apolipoprotein E, which plays an important role in 
prolonging the drug circulation time in vivo (Sun W et al., 2004). 
Compare to other nanoformulations, the advantages of nanosuspensions include (1) 
Higher drug loading (because drug is suspended in solid state) leads to lower volume of 
administration. (2) Nanosuspensions present reduced toxicity by using relatively low 
quantity of stabilizing surfactants (Keck CM and Müller RH, 2006). (3) They can be given 
by various routes of administration, such as oral, parenteral, pulmonary and ocular 
pathways, due to their particle size within a nano range (Kesisoglou F et al., 2007; Müller 
RH and Jacobs C, 2002; Pignatello R et al., 2006). (4) Nano-particles have a high 
possibility to be taken up by the macrophages in the liver, spleen and lung. 
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Subsequently, the particles may dissolve in the macrophages slowly and diffuse out of 
the cells to provide a depot effect (Xiong R et al., 2008; Andes D, 2003; Ganta S et al., 
2009).  
Recently, there are two basic technologies to prepare nanosuspension: media milling 
and high-pressure homogenization. Four commercial nanosuspension products have 
been obtained by media milling.  Nanosuspensions can be formed by breaking larger 
micron-sized particles down by milling. A new surface area is formed which leads to an 
increase in free-energy in the system. The system becomes unstable due to the 
increased energy resulting from the creation of new surface area of the milled particles. 
To correct this energy imbalance, the small particles tend to agglomerate to decrease 
the surface area and re-stabilize the system. To overcome the self-correction step, a 
surface active agent is added during the milling step. 
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1.4. Central Composite Design (CCD) 
During the formulation preparation process, many variables show a marked influence on 
the physicochemical properties of nanosuspensions. Such as milling time, surfactant, 
surfactant concentration, drug concentration, and so on. Therefore, it is essential to have 
a clear understanding about how preparation parameters determine particle 
characteristics and how these variables interact with each other.  
Generally, the impact of each variable can be assessed by varying one variable while 
keeping other factors constant. Such an empirical method is acceptable only when the 
factors are independent of one another. However, it fails to take into account the 
interactions between these factors. Factorial designs enable all factors to be varied 
simultaneously, thus allowing quantization of the effects caused by independent 
variables and interactions between them; thus, it is an ideal technique for formulation 
studies (McLeod AD et al., 1988; Molpeceres J et al., 1996). However, in such studies, 
an increase in the number of factors markedly increases the number of experiments to 
be carried out. An alternative approach under these circumstances is to include extra 
center and star points in a two-level factorial design, which is known as central 
composite design (CCD). CCD is composed by the factorial experiment, axial points and 
center point. This structure makes it have a better prediction capability than factorial 
design (Bolton S, 1983; de Boer T et al., 1999). 
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1.5. Lung Cancer 
Lung cancer is the leading cause of death due to cancer, approximately 1/3 of cancer 
deaths. According to the NCI, there are 226,160 new lung cancer cases yearly and 
160,340 deaths in the United States in 2012. Lung cancer patients experience 40% 
relapse rates and 15% overall survival rates over five years. Considering these numbers, 
much needs to be done in the treatment of lung cancer.  
 Based on morphology, there are two types of lung cancer namely small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for 70% of all lung 
cancer cases. The current treatment options in lung cancer are surgery, radiation, 
chemotherapy, and targeted therapy. SCLC responds to chemotherapy better than 
NSCLC and chemotherapy is the major treatment option for SCLC. The major areas of 
focus for SCLC need to be prevention (smoking) and early detection; whereas in NSCLC 
the latter two are important but treatment options need to be improved. 
NSCLC is divided by stages based on the localization of the tumor, lymph node 
involvement, and metastases to other places. Stage I has no nodular involvement or 
metastases. Stage II has nodular involvement in nearby lymph nodes but no metastases 
or has no nodular involvement or metastases but has a tumor size so large that it 
invades the chest wall but does not cause obstruction of organs. Stage III has nodular 
involvement in distant lymph nodes but has no metastases or a tumor size so large that 
it invades the chest wall and causes some obstruction. Stage IV has distant metastases 
and metastases to a different lobe of the lung. 
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Stage I, II, and III are considered early stages and treatment focuses on radiation and 
surgery. Chemotherapy is used in combination with radiation and surgery in earlier 
stages, and is only used as palliative treatment in stage IV. Palliative treatment includes 
reduction of tumor size which when too large may cause problems such as intense pain 
or effect on vital organs. Chemotherapy regimens are platinum based with the agents 
cisplatin and carboplatin being used in combination with agents such as paclitaxel, 
docetaxel, topotecan (TPT), irinotecan (CPT-11), vinorelbine, and gemcitabine. In 
recurrent NSCLC in which platinum agents had previously been used docetaxel may be 
used and in case of failure the epidermal growth factor receptor (EGFR) inhibitor 
erlotinib can be used. Based on the NCI record, vinorelbine, paclitaxel, docetaxel, 
gemcitabine have shown increased survival outcomes, although minimal. The 
camptothecin derivatives are considered second line, in this way; CZ48 may offer a good 
alternative. 
We then chose to use the tumor bearing Athymic Swiss nude mouse model for efficacy 
studies because it is a well-established cancer model. The cell line we chose to use was 
the more aggressive H460 cell line (Mattern J et al., 1985). We deside to characterize 
the pharmacokinetics of nanosuspension formulations in the Athymic Swiss nude mice 
before starting the efficacy studies. 
1.6. Concepts of Passive Targeting 
Tumor blood vessels are generally characterized by abnormalities such as high 
proportion of proliferating endothelial cells, pericyte deficiency and aberrant basement 
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membrane formation leading to an enhanced vascular permeability. Particles, such as 
nanocarriers (in the size range of 20–200 nm), can extravasate and accumulate inside 
the interstitial space (Danhier F et al., 2010). Endothelial pores have sizes varying from 
10 to 1000 nm (Torchilin VP, 2000). Moreover, lymphatic vessels are absent or non-
functional in tumor which contributes to inefficient drainage from the tumor tissue. 
Nanocarriers entered into the tumor are not removed efficiently and are thus retained in 
the tumor. This passive phenomenon has been called the “Enhanced Permeability and 
Retention (EPR) effect,” discovered by Matsumura and Maeda (Matsumura Y and 
Maeda H, 1986). The abnormal vascular architecture plays a major role for the EPR 
effect in tumor for selective macromolecular drug targeting at tissue level that can be 
summarized as follows and illustrated in Figure 5: 
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a. Normal Tissue                                         b. Tumor Tissue 
    
Figure 5 Differences between Normal and Tumor Tissues that Explain the 
Passive Targeting of Nanocarriers by the Enhanced Permeability and 
Retention Effect.  
a. Normal tissues contain linear blood vessels maintained by pericytes. Collagen fibers, 
fibroblasts and macrophages are in the extracellular matrix. Lymph vessels are present. 
B. Tumor tissues contain defective blood vessels with many sac-like formations and 
fenestrations. The extracellular matrix contains more collagen fibers, fibroblasts and 
macrophages than in normal tissue. Lymph vessels are lacking. (Heldin CH et al., 2004) 
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Summary  
This suvey of the literature reveals that CZ48, a propionate ester of CPT, was 
synthesized with superior lactone stability over CPT both in vitro and in vivo. However, 
the poor solubility of CZ48 is a big challenge to administer the drug. In addition, Topo- 
inhibitors are S-phase cell-cycle specific and in vitro and in vivo studies have suggested 
that, for efficacy, prolonged exposure to low concentrations might indeed be more 
relevant than short-term exposure to high concentrations. Therefore, developing a 
sustained release nanoformulation for CZ48 could overcome the administration 
challenge, provide a prolonged exposure of CPT at the site and the passive targeting of 
nanoformulation to RES rich organs might have additional merits for the CZ48 
chemotherapy. 
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Chapter 2  Hypotheses and Specific Aims 
2.1 Central Hypothesis 
In this study, nanosuspensions are selected to formulate and to modify the 
pharmacokinetics of CZ48. We propose that nanosuspensions can be prepared with the 
optimal characteristics to deliver CZ48 at a sustained rate. By the continuous delivery of 
CZ48, a low but effective level of active form of CPT will be constantly converted from 
the prodrug, CZ48, to achieve a significant anticancer activity and toxicity alleviation. We 
hypothesize that optimized nanosuspension of CZ48 can provide sustained plasma 
levels of active CPT. 
2.1. Specific Aims 
2.1.1. Aim I  
To prepare and characterize CZ48 nanosuspensions with different particle sizes 
We hypothesize that CZ48 nanosuspensions with a distinct particle size can be 
developed and the formulations offer a sustained release of CZ48.  We will also use the 
CCD method to optimize the nanosuspensions’ properties. 
2.1.2. Aim II 
To determine the pharmacokinetics and organ distribution of CZ48 and CPT from the NS 
formulations of CZ48 in rodents 
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We hypothesize that a prolonged drug exposure in vivo will be achieved upon the 
administration of CZ48 nanosuspensions.  
2.1.3. Aim III 
To determine the efficacy of CZ48 nanosuspension in tumor-bearing athymic mouse 
model 
We hypothesize that the lead formulation will overcome the limitations of CZ48 and be 
proven a significant efficacy with a higher tolerable dose in H460 tumor mouse model.  
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Chapter 3  Materials and Methods 
3.1. Materials 
3.1.1. Chemicals and Materials 
 Acepromazine Maleate Injection (Phoenix, St .Joseph, MO, USA) with Ketamine 
and xylazine were mixed and injected intramuscularly to provide anesthesia 
during cannulation surgery and for euthanasia at the end of studies conducted in 
rats. 
 Acetonitrile (ACN) HPLC-grade (EM Science, Gibbstown, NJ, USA) was used in 
mobile phase for HPLC assay, as well as the extraction of drug from in vivo 
samples for HPLC analysis. 
 CPT was purchased from Sigma-Aldrich (St. Louis, MO, USA). CPT was used as 
standard for HPLC assays. 
 CZ48 and CZ44 were kindly given by CHRISTUS Stehlin Foundation for Cancer 
Research (Houston, TX, USA) as gift. CZ44 was used as internal standard for 
HPLC assay. 
 Dimethylsulfoxide (DMSO) analytical grade (J.T. Baker Chemical Co., 
Phillipsburg, NJ, USA) was used as solvent for stock solutions of CZ48, CPT and 
CZ44, as well as a constituent of the cosolvent formulation used for CZ48 studies. 
 Double distilled water was produced by a MiliporeMilli-Q system (Billerica, MA, 
USA). 
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 Ethanol  (EMD, Gibbstown, NJ, USA) was used in the preparation of CZ48 
cosolvent formulation, 
 F-60 and F-108 were kindly provided by BASF (USA). Tween-80 (T-80) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). They are used for 
formulation preparation. 
 Glacial acetic acid (J.T. Baker Chemical Co., Phillipsburg, NJ, USA) was used to 
keep the pH of the mobile phase at 3.0 in the CZ48 HPLC assay. 
 Heparin sodium salt (Sigma Chemical Co., St. Louis, MO, USA) was used to 
heparinize micro-centrifuge tubes for blood collection in the PK studies. 
 Phosphate-buffered saline (PBS) that was made from 0.4 mM KH2PO4 (Sigma 
Chemicals Co., St. Louis, MO, USA), 2 mM K2HPO4 (Fisher Scientific Co., Fair 
Lawn, NJ, USA), and 140 mM NaCl (Eastman Kodak Co., St. Louis, MO. USA) 
was prepared as a receptor medium for in vitro release studies. 
 Polyethylene glycol 400 (PEG 400) (Merck, Darmstadt, Germany) was used as a 
component of cosolvent formulations of CZ48. 
 Sodium choride (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in 
double distilled water to prepare normal saline solution. 
3.1.2. Surgical Instruments and Supplies 
 Alcohol wipes (Webcol® Alcohol Preps, Kendall Healthcare Products Co., 
Mansfield, MA, USA) were used to disinfect the animal skin surface prior to 
injection or surgery. 
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 Cotton swabs (Q-tips, 6 inch) (Tyco healthcare group LP, Mansfield, MA, USA) 
were used in animal surgery procedures in PK studies. 
 Inserts (small volume) for samples in vials for HPLC analysis: Conical, clear 
glass, 150 µl (Waters Corp., Milford, MA, USA) were used for PK studies with low 
sample volumes (25-150µl) for HPLC assay. Flat bottom, clear glass, 250 µl (J G 
Finneran, Vineland, NJ) were used for larger plasma or tumor sample volumes 
(50-250µl) in microdialysis or efficacy studies for HPLC assay. 
 Insulin syringes (1/2 cc, sterile) (Becton Dickinson & Co., Rutherford, NJ, USA) 
were used to administer the anesthesia intramasularly.   
 Membrane filters (47mm, 0.45 µm, hydrophilic polypropylene; Pall Corp., Ann 
Arbor, MI, USA) were used to filter the mobile phase for the HPLC assays. 
 Needles (23G1, sterile single use, Precision Glide Needle, Becton/Dickinson and 
Company. Sparks, MD, USA) were used with syringe (1 CC, sterile single use, 
Becton/Dickinson and Company. Sparks, MD, USA) for i.v. drug administration 
and blood sampling from canular. 
 Pipette tips (disposable, 1-10 µl, 10-100 µl  and  100-1000 µl, VWR, West 
Chester,PA, USA) were used  with appropriate pipettes (VWR, West Chester,PA, 
USA) to measure solutions for all experiments. 
 Polyethylene tubing (I.D. 0.023", O.D. 0.038", Becton/Dickinson and Company. 
Sparks, MD, USA) was used to extend the cannula for convenient drug 
administration and blood sampling. 
 Standard silicone tubing (I.D. 0.025", O.D. 0.047", Helix Medical, Carpinteria, CA, 
USA) were used as cannula. 
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 Surgical absorbent pads (Medline, Mundelein, IL, USA) were used during animal 
studies. 
 Surgical suture (size 4-0, Deknatel ) 
 Syringe filters (0.45 µm, HPLC certified) were used to filter CZ48 cosolvent 
during preparations. 
3.1.3. Equipment and Apparatus 
 Beckman Coulter Microfuge 22R Refrigerated Microcentrifuge was used to 
separate plasma from blood, and sample preparation. 
 Column (XTerra ® RP18, 5 m particle, 46  150 mm, Waters) was used for all 
HPLC analysis.  
 Dissection equipment set (Miltex ®, Thomas Scientific, Swedesboro, NJ, USA) 
was used for surgery and cannulation of rats, as well as organ dissection from 
rats and mice. 
 Electronic balance, 0.0001 g sensitivity (Mettler AE100, Mettler Instrument 
Corporation, Hightstown, NJ, USA) was used to weigh all solid chemicals and 
animal organs. 
 HPLC system (515 HPLC pumps, 717 plus autosampler, and 2475 multi  
fluorescence detector, Waters). 
 pH meter (IQ 240, Scientific Instrument, Carlsbad, CZ, USA) was used to 
measure the pH of the mobile phase. 
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 Shaking water bath (Model YB-521, American Scientific Products) was used in 
the preparation of cosolvent formulation and the in vitro release study. 
 Vortex mixer (Vortex-Genie 2, Scientific Industries, Inc., Bohemia, NY, USA) was 
used for mixing liquid samples and solutions. 
 WinNonlin professional version 3.3 (Pharsight Corporation, Mountainveiw, CA, 
USA) computer program was used for pharmacokinetic analyses and parameter 
calculation. 
3.1.4. Animals 
 Male Sprague Dawley rats (250 ~ 300 g), purchased from Harlan Laboratories 
(Houston, TX), were used for pharmacokinetic and organ distribution studies. 
 Athymic Swiss nude mice (25 ~ 30 g) (CHRISTUS Stehlin Foundation for Cancer 
Research in Houston, TX, USA) were used for all PK, organ distribution and 
efficacy studies. 
3.2. Methods 
3.2.1. CZ48 Nanosuspension Preparation 
CZ48 nanosuspensions were prepared by media milling method (shown as Figure 6), as 
described earlier (Kocbek P et al., 2006). In brief, the mixture of CZ48, stabilizers and 
water were placed in a 7 ml scintillation vial. Certain amount of glass beads (0.5 ~ 0.75: 
0.75 ~ 1: 1 ~ 1.3 μm at 1:1:1) were then added as milling agents. The mixture was milled 
at the rate of 1,600 rpm for several hours. Each formulation was prepared in duplicate. 
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3.2.2. CZ48 Nanosuspension Characterization 
The particle size, polydispersity index (PI), and zeta potential of each formulation were 
measured by ZetaPals (Brookhaven Instruments, Holtsville, NY). Samples were diluted 
to an appropriate concentration by filtered, double-distilled water. Each sample was 
measured three times, and the average values were employed. 
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Figure 6 Wet Media Milling Technique for Nanosuspensions Preparation 
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3.2.3. CZ48 Nanosuspension Optimization-Experimental Design 
A Central composite design (CCD) was implemented for the optimization of various 
response properties. Based on the results of initial studies, the combination of Pluronic® 
F-108 (F-108) and T-80 as stabilizers yields nanosuspensions with preferred properties 
and the concentration of CZ48, F-108/CZ48 ratio and T-80/CZ48 ratio were found to 
influence the properties (particle size and zeta potential) of CZ48 nanosuspensions 
significantly. In this study, a three-factor five-level CCD was undertaken to investigate 
the main effects and the interactions of these three critical influencing factors on the two 
responses (particle size, zeta potential). During the optimization trails, the investigate 
range of each variable and the experimental codes were shown in Table 1. In the 
present design, 20 experiments were carried out to determine the model coefficients.  
Two optimal experimental responses were studied: Y1, particle size, Y2, zeta potential, 
and those responses were modeled by the following model quadratic equation: 
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Where X1, X2 and X3 correspond to the studied factors, Y is the measured response, b0 
is an intercept, b1 ~ b9 are the regression coefficient.  
Data were analyzed by nonlinear estimation using STATISTICA® software. The results of 
these experiments were compared by Analysis of Variation (ANOVA) to determine if the 
factors and the interactions between the factors were significant. T-tests were used to 
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obtain parameters statistically significant in the regression model at α = 0.05 level. An F-
test was performed to determine whether there was an overall regression relationship 
between the response Y and the entire set of variables X at a 95% level of significance.  
Response surface delineation was performed according to the fitting model. The surface 
response plots for particle size and zeta potential as functions of influencing factors were 
conducted by fixing the least significant factor at the optimized value. The minimum 
response values and its corresponding experimental settings were solved from the 
regression equation (2) and (3) by performing a Visual-Basic-language based computer 
script calculation with step width of 0.1.  
A verification test was conducted to prove the accuracy and usefulness of this statistic 
model under the optimized experimental conditions. The particle sizes of 
nanosuspension formulations prepared under these conditions were analyzed (n=6). 
3.2.4. CZ48 Nanosuspension Stability 
The physical stability of the CZ48 nanosuspensions was evaluated at 4 ± 2 °C and 25 ± 
2 °C. Prepared nanosuspensions were divided into two parts and kept at 4 °C and 25 °C, 
and the changes in particle size, PI and zeta potential were recorded over the period of 3 
months.  
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3.2.5. In-vitro Drug Release Study 
In-vitro release study of CZ48 from cosolvent and nanosuspensions of two particle sizes 
in both PBS and human plasma were conducted to compare the in-vitro rates and 
extents of CZ48 from different formulations by Dialysis Bag Diffusion Technique (Figure 
7) (Kostanski JW and DeLuca PP, 2000). 
3.2.5.1 Conditions for HPLC Assay of CZ48 and CPT in Aqueous Solution 
The HPLC assay was based on a previously developed isocratic HPLC method (Li XH, 
2004) for the simultaneous quantifications of CZ48 and CPT concentrations in aqueous 
solution. The concentration ranges for CZ48 and CPT were both 12.5 ~ 200 ng/ml. We 
used a reverse phase C8 column (4.6 mm x 250 mm, particle size of 5 µm) and a 
fluorescence detector with excitation and emission λ of 360 & 455 nm, respectively. The 
mobile phase consisted of methanol: acetonitrile: 2% triethylamine (30:28:42, by 
volumes) with the pH adjusted to 5.0 with acetic acid and a flow rate of 1 ml/min was 
used to elute the column. The internal standard used was CZ44. The peak area ratios of 
CZ48/CZ44 or CPT/CZ44 were plotted against the corresponding CZ48 or CPT 
concentrations. Linear regression was used to determine the slopes of the curves and 
the y-intercepts. The HPLC assay was repeated to establish within-day (n = 3) and 
between-day (n = 6) variability. 
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Figure 7 Dialysis Bag Diffusion Technique for In vitro Release Study 
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3.2.5.2 In-vitro CZ48 Release from Cosolvent, NS-S, and NS-L in PBS and 
Human Plasma 
The in-vitro release studies were performed in human plasma and phosphate buffered 
saline (PBS) solution (pH 7.4) with 0.2 wt% T-80 (to maintain sink condition), 
respectively, using dialysis bag diffusion technique reported by Kostanski and DeLuca 
(Kostanski JW and DeLuca PP, 2000). Approximately 1 mg of the formulation was 
transferred to the dialysis bag (M.W. cut off 6000 - 8000 Da) in a shaker with the speed 
of 100 rpm at 37 ± 0.5 °C. Samples (200 μl) were withdrawn at the predetermined time 
points of 0.25, 0.5, 0.75, 1, 2, 3, 4, and 6 h in PBS or 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 
24, 32 and 48 h in plasma. Samples were assayed for CZ48 by a validated HPLC 
method.  
The profiles of cumulative amount of CZ48 released versus time were constructed. The 
extent of CZ48 release was calculated as the total release at 6 h (PBS) or 48 h (plasma). 
To characterize the release profiles, 1st-order, Higuchi, Peppas, Hixson-Crowell and 
Weibull equations were fitted to the release profiles. 1st-order (Equation 2) as log percent 
drug remaining vs. time, Higuchi‟s model (Equation 3) as cumulative percentage of drug 
released vs. square root of time and Hixson-Crowell model (Equation 5) as the cube root 
of the percentage of drug remaining in the matrix vs. time.  
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3.2.5.3 Statistical Data Analysis 
Statistical criteria including the adjusted coefficient of determination (R2 adjusted), the 
standard deviation of the residual (MSE_root) and Akaike information criterion (AIC) 
were used to evaluating the goodness of fit of a model. Release kinetic parameters were 
obtained by nonlinear regression based on the best fit model using MATLAB software. 
Data was presented as mean ± standard deviation (n = 3). The significant difference in 
the parameters among the groups will be statistically evaluated by one-way ANOVA 
followed by post hoc Tukey’s test at p<0.05 using MINITAB student 12 software.  
3.2.6. Pharmacokinetic and Biodistribution Studies of CZ48 and CPT    
from CZ48 nanosuspensions in Sprague-Dawley (SD) rats 
The aim of this study was to establish the PK of CZ48 and its metabolite, CPT, from the 
cosolvent, NS-S and NS-L upon intravenous (i.v.) administration to SD rats. 
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3.2.6.1 Preparation of Dosing Formulations  
CZ48 cosolvent (0.8 mg/ml) was prepared as DMSO: PEG400: Ethanol (2:2:1 by 
volume). CZ48 nanosuspensions were diluted using the double distilled water to the 
proper concentration at 10 mg/ml. 
3.2.6.2 Rats Study Protocol 
All experiments were conducted in accordance with National Institutes of Health (NIH) 
Guideline for the Care and Use of Animals and with approved animal protocol from the 
University of Houston Institutional Animal Care and Use Committee (IACUC). Male SD 
rats (250 ~ 300 g) were housed under standardized condition (12 hours light / dark 
schedule). All animals were kept 1 week prior to experiments for acclimation. Then, the 
rats were randomly divided into experimental groups (6 rats per group) for treatment with 
CZ48 formulations. Before CZ48 administration, a cannula was introduced into the 
jugular vein for injection of formulations and blood collection. The rats were anesthetized 
by anesthesia cocktail (Ketamine 50 mg/ml, Xylazine 3.3 mg/ml and Acetopromazine 3.3 
mg/ml) prior to the jugular vein surgery and administrated carprofen subcutaneously 
after the surgery. 
3.2.6.3 Pharmacokinetic Study 
Rats were dosed with CZ48 cosolvent at 5 mg/kg (control group), CZ48 NS-S at 25 
mg/kg, or CZ48 NS-L at 25 mg/kg through jugular vein cannula. Blood sample (200 µl) 
were withdrawn at 5, 15, 30, 45 min, and 1, 2, 3, 4, 6, 8, 10 and 24hr post dose from 
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jugular vein cannula. The volume of blood removed at each sampling time was replaced 
with an equal volume of saline. And the blood samples were immediately centrifuged at 
10, 000 rpm for 20 min to separate the plasma fraction from the blood cells, and the 
plasma samples were stored at -80 C until HPLC analysis. 
3.2.6.4 Organ Distribution Study 
At 15 min, 30 min, 2 h, 4 h, 8 h, and 24 h after the dose injection, rats (n=4 per time 
point) were anaesthetized with anesthesia cocktail (Ketamine 50 mg/ml, Xylazine 3.3 
mg/ml and Acetopromazine 3.3 mg/ml), and subsequently euthanized by drawing all the 
blood from the abdominal aorta. Next to blood, heart, liver, spleen, lung, kidney and 
brain were collected. Organs were weighted and homogenized. All samples were stored 
at -80 C until HPLC analysis.      
The organ/plasma partition coefficient (Kp) of CZ48 and CPT for the heart, liver, spleen, 
lung, kidney and brain were obtained experimentally from the organ/plasma ratios 
toward the end of the study by the following equation (Chow EC et al., 2011): 
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3.2.6.5 HPLC Assay of CZ48 and CPT in Rat Plasma and Tissue Samples 
The HPLC assay was based on a well-established gradient HPLC method (Liu X et al., 
2010) for the simultaneous quantifications of CZ48 and CPT concentrations in plasma 
samples. The concentration ranges for CZ48 and CPT were both 0.78 ~ 800 ng/ml. We 
used a reverse phase C8 column (4.6 mm x 250 mm, particle size of 5 µm) and a 
fluorescence detector with excitation and emission λ of 360 & 455 nm, respectively. The 
optimized method used a binary gradient mobile phase with 0.1% acetic acid water as 
mobile phase A (pH 3.0) and acetonitrile (ACN) as mobile phase B. A flow rate of 1.2 
ml/min was used with a 10 l injection volume. The time program of the gradient was 
listed in Table 1. Each injection was followed by a 3 ~ 5 min equilibrium time before the 
next injection. The eluted peaks were monitored at excitation and emission wavelengths 
of 360 and 455 nm, respectively. CZ44 was used as internal standard. The peak area 
ratios of CZ48/CZ44 or CPT/CZ44 were plotted against the corresponding CZ48 or CPT 
concentrations. Linear regression was used to determine the slopes of the curves and 
the y-intercepts.  
 57 
 
Table 1 HPLC Mobile Phase Gradient Conditions for Analysis of CZ48, CPT  
Time (min) Flow rate (ml/min) A% B% 
0.00 1.2 80.0 20.0
15.00 1.2 78.0 22.0
25.00 1.2 55.0 45.0
30.00 1.2 20.0 80.0
31.00 1.2 0.0 100.0 
32.00 1.2 80.0 20.0
34.00 1.2 80.0 20.0
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3.2.6.5.1 Standard Stock and Working Solutions 
Standard stock solutions of CZ48, CPT and internal standard (IS) were all prepared in 
DMSO at concentrations of 1.0 mg/ml. Stock solutions were stored at -20 C until they 
were used for working solutions by adding appropriate volume of ACN. 
3.2.6.5.2 Preparation of CZ48 and CPT Rat Plasma Samples 
A portion of 100 l blank mouse plasma, spiked plasma or pharmacokinetics study 
plasma was transferred to a 1 ml test tube. And then 500 l of IS working solution (40 
ng/ml) was added to the mixture and vortex for 10 s. The mixture was centrifuged at 
10,000×g for 15min, and the upper layer was transferred to a clean tube and evaporated 
to dryness using an evaporator under a stream of nitrogen. Then, the dried extract was 
reconstituted in 200 l of water/ACN (50/50, v/v diluent) and a 10 l aliquot was injected 
into the chromatographic system. Within-day (n = 3) and between-day (n = 6) variability 
were also established for both CZ48 and CPT. 
3.2.6.5.3 Preparation of CZ48 and CPT Rat Organ Samples 
Rat organ samples (0.5 g each, heart, liver, spleen, lung, kidney, or brain) were minced 
and placed into 7 ml vials and 1 ml of normal saline was added to each sample, The 
organ samples were then homogenized by a tissue homogenizer. The internal standard 
working solution in ACN (40 ng/ml, 500 l) was added to 100 l of blank organ 
homogenate, spiked organ homogenate or biodistribution study organ homogenate. The 
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mixture was vortex for 10 s, and centrifuged at 10,000×g for 15min, and the upper layer 
was transferred to a clean tube. The extract was evaporated to dryness using an 
evaporator under a stream of nitrogen and reconstituted in 200 l of water/ACN (50/50, 
v/v diluent) and a 10 l aliquot was injected into the chromatographic system. Within-day 
(n = 3) and between-day (n = 6) variability were also established for both CZ48 and CPT. 
3.2.6.5.4 Determination of Extraction Recovery 
The percent drug recovery was calculated as the ratio of the slope of the plasma 
standard curve to that of the aqueous assay, and accounting for the dilution factor 
involved. This value can provide the information on the extent of drug loss during the 
extraction procedures. 
3.2.6.6 Pharmacokinetic Analysis 
Pharmacokinetic and statistical data analyses were performed using WinNonlin 
(Professional 3.0 Version). WinNonlin was used to model CZ48 and CPT profiles using a 
compartmental model for rat samples to estimate the area under the curve (AUC), 
clearance (CL), elimination rate constant (ke), volume of distribution (Vd) and elimination 
half-life (t1/2) for the three formulations.  
3.2.6.7 Statistical Analysis 
Statistical significance was evaluated by ANOVA followed by Tukey’s post-hoc for more 
than two groups with a P<0.05 for significance. MINITAB student 15 was used for the 
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statistical analysis. In case of rat biodistribution study, sparse sampling was used in the 
collection of in-vivo data; that is, each animal contributed with a single observation and 
the area under the concentration-time curve was constructed from the mean plasma 
concentration from multiple rats at each time point. 
3.2.7. Pharmacokinetic and Biodistribution Studies of CZ48 and CPT 
from CZ48 nanosuspensions in Swiss Nude Mice 
The aim of this study was to establish the PK of CZ48 and its metabolite, CPT, from the 
cosolvent, NS-S and NS-L upon intravenous (i.v.) administration to Swiss Nude Mice.  
3.2.7.1 Preparation of Dosing Formulations 
CZ48 cosolvent (0.8 mg/ml) was prepared as DMSO: PEG400: Ethanol (2:2:1 by 
volume). CZ48 nanosuspensions were diluted using the double distilled water to the 
proper concentration at 10 mg/ml. 
3.2.7.2 Mice Study Protocol - Pharmacokinetic and Organ Distribution 
Study 
All experiments were conducted in accordance with NIH Guidelines for the Care and 
Use of Animals and with approved animal protocol from the University of Houston 
IACUC. Male Swiss athymic nude mice (20 ~ 25 g) were a gift from Stehlin Foundation 
for Cancer Research (Houston, TX, USA). Mice were maintained in individual ventilated 
cages under standard laboratory conditions (12-hour light/dark cycle) with free access to 
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food and water. Then, the mice were randomly divided into experimental groups (6 rats 
per group) for treatment with CZ48 formulations. 
Mice were dosed with CZ48 cosolvent at 5 mg/kg (control group), CZ48 NS-S at 25 
mg/kg, or CZ48 NS-L at 25 mg/kg through tail vein. There will be six groups of mice for 
each formulation which will be named as 15 min, 30 min, 2 h, 4 h, 8 h, and 12 h. The 
animals of 15 min and 30 min groups were sacrificed after 15 min and 30 min post dose 
under anesthesia using Avertin (tribromoethanol and amyl alcohol) based on the 
Christus Stehlin Foundation Standard Operating Procedure (SOP) for mouse anesthesia. 
A terminal blood collection will be withdrawn from the heart, and the whole body will be 
flushed by normal saline. Then heart, liver, spleen, lung, kidney, gall bladder, and brain 
will be harvested.  
The animals of 2 h group, before sacrifice, only one additional blood sample was taken 
at 1 h time point from facial vein, then follow the same procedure as the 15 min and 30 
min groups. The animals of 4 h, 8 h, and 12 h groups were treated the same as them in 
2 h group. One additional blood sample for each mouse was collected from facial vein 
before sacrifice, which was at 3 h for 4 h group, 6 h for 8 h group, and 10 h for 12 h 
group. In this way, the animals in 15 min and 30 min groups were only taken one blood 
sample for each mouse. The others were taken two blood samples for each mouse. 
The blood samples were immediately centrifuged at 10, 000 rpm for 20 min to separate 
the plasma fraction from the blood cells, and the samples were stored at -80 C until 
HPLC analysis.  
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3.2.7.3 HPLC Assay of CZ48 and CPT in Mouse Plasma and Tissue Samples 
The HPLC assay was based on a well-established gradient HPLC method (Liu X et al., 
2010) for the simultaneous quantifications of CZ48 and CPT concentrations in plasma 
samples. This HPLC method also has been validated in section 3.2.6.3 in animal organs.  
The pharmacokinetic paramters and Kp were also calculated following the same 
procedures as we did for the study in the rats. 
3.2.7.4 Statistical Analysis 
In case of mice study, sparse sampling was used in the collection of in-vivo data; that is, 
each animal contributed with a single observation and the area under the concentration-
time curve was constructed from the mean plasma concentration from multiple rats at 
each time point. 
3.2.8. CZ48 Nanosuspension Efficacy Studies 
Before testing the efficacy of CZ48 nanosuspension in vivo, we first evaluated the CPT 
circulation by different formulation dosage. NS-S was selected as lead formulation to 
perform the efficacy study. NSCLC H460 cell lines were purchased from American Type 
Culture Collection (ATCC, mansaas, VA) and were widely used in the NSCLC efficacy 
test in subcutaneous tumor model because of its fast growth rate and high implant 
successful rate.  
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3.2.8.1 Passage of Tumor into Mice 
The cell lines had been subcultured and frozen (- 40 °C) after the cell culture work to 
maintain supply. The subculturing was done to divide the cells from one flask to four 
flasks. The subcultured cell lines were counted using a Z2 coulter counter and were 
recorded as cells per ml. After counting, the cells were placed in the freezer (- 40°C) and 
these were the cells used in the efficacy studies for this project. 
For the efficacy studies, the cells were thawed, detached using trypsin, and centrifuged. 
The pellet was suspended in RPMI 1640 medium at a concentration of 107 cells/ml. One- 
quarter ml of the suspension was injected subcutaneously in the mid dorsal portion of 
four to six mice with a 25 gauge needle for tumor growth. After two weeks, the tumors 
were taken out for passage into all the study mice. The mice were sacrificed and the 
tumors were removed, pooled, minced up, and centrifuged. The supernatant was 
removed and 1 part of RPMI 1640 media was added to two parts of the tumor pellet and 
cells were aspirated with 16 gauge needle. About 100 µl of the suspension was injected 
in the mid-back of the study mice in order to induce the tumor for growth. 10 mice were 
used in each group for the dose response study based on the power analysis using 
MINITAB 14. 
3.2.8.2 Randomization of Mice into Dosing Groups 
When the estimated tumor volumes were about 100 mm3, the mice were weighed and 
tumor volumes measured. Calipers were used to measure tumor volume which is 
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defined as the product of the tumor length (L), width (W), and height (H). The mouse 
weight and tumor volume were added to Microsoft FoxPro 7.0 with the mouse ID number 
that was earlier generated using FoxPro 7.0 and the program was used to randomize the 
mice into groups. 
3.2.8.3 Study Design 
The mice were dosed and assessed twice weekly. The assessment included body 
weight for toxicity, as well as tumor size and survival for efficacy. If the body weight loss 
was >15% or the tumors were >7000 mm3, the mice were sacrificed. The endpoints of 
the study were tumor growth rate (defined as V/V0, V is the tumor volume on the day of 
sacrifice and V0 is the tumor volume on the first day of dosing), toxicity (body weight 
loss >15 %), and survival. 
3.2.8.4 Statistical Data Analysis  
MINITAB student 14 was used for most of the statistical analysis. ANOVA with Tukey’s 
post-hoc was used for comparisons of tumor growth rate among groups. SASS was 
used for Kaplan-Meier survival analysis among groups in the efficacy studies. 
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Chapter 4 Results 
The results of this investigation are summarized in the following subtopics: (1) 
Preparation, optimization and characterization of CZ48 nanosuspensions; (2) Plasma PK 
and organ distribution of CZ48 and CPT after CZ48 nanosuspensions i.v. administration 
to rats; (3) Plasma PK and organ distribution of CZ48 and CPT after CZ48 
nanosuspensions i.v. administration to mice; (4) Comparison of formulation effects 
between species; (5) Proof of concept efficacy of NS-S in lung cancer tumor bearing 
mouse model  
4.1. Preparation, Optimization and Characterization of CZ48 
Nanosuspensions 
4.1.1. CZ48 Nanosuspensions Preparation  
Before the statistic experimental design was conducted, three qualitative factors (the 
type of stabilizers, concentration of stabilizers, and milling time) were prescreened by 
varying only one factor at a time. Since the influence of each factor on the 
physicochemical properties unknown when the prescreening study was conducted, the 
experimental condition was set arbitrarily as follows: drug concentration at 1%, stirring 
speed at 1,600 rpm.  
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4.1.1.1 Influence of Stabilizers 
In order to identify stabilizer candidates for the nanosuspensions of CZ48, five different 
stabilizers, polyvinylpyrrolidone (PVP) K40, polyvinyl alcohol (PVA), Pluronic F68 (F-
68), Pluronic F108 (F-108), and polysorbate 80 (T-80) in three concentrations as 
stabilizer/CZ48 ratio at 1:1 (H), 1:4  (M), and 1:10 (L) were screened as well as their 
combination with T-80 (L:L). The results were shown in (Table 2). The particle size in 
nanosuspensions stabilized with PVA, F-108 and T-80 is significantly smaller than those 
stabilized with PVP 40 and F-68. However, only F-108 and F-68 could further decrease 
the particle size significantly when higher concentrations were used (p<0.05).  Moreover, 
nanosuspensions with a combination of with T-80 at a very low concentration resulted in 
a comparable or significantly smaller particle size than those with the single stabilizer 
alone at a much higher concentration. As stabilizers in combination were reported to 
achieve a better long-term stabilization, and T-80 uniquely facilitates a longer drug 
circulation in blood (Lück M et al., 1998), we preferably used stabilizers combing T-80 
with another other type of stabilizer for our CZ48 nanosuspensions. According to the 
screening data in (Table 2), a smaller size (366 ± 13.2 nm) was obtained by using 
combined F-108 and T-80 as the stabilizer without any formulation optimization. This is 
consistent with an earlier report that F-108 is excellent in stabilizing nanoparticles, due to 
its strong affinity to the surface of nanoparticles (Höfig I et al., 2012). In addition, the 
combination of F-108 and T-80 was the only one pair that can further reduce the particle 
size by increasing the milling time. The stabilizers of combined F-108 and T-80 were 
selected for further CCD optimization. 
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In addition, the polydispersity for all the nanosuspension formulations with different 
stabilizers were within the acceptable range (0 ~ 0.3), indicating a narrow particle size 
distribution. The zeta potential of the nanosuspensions was all negative within the range 
of -19 ~ -32 mV (Table 2). 
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Table 2 Effect of Different Stabilizers and Combinations with T-80 on Particle 
Size, PI and Zeta Potential of Nanosuspension by Media Milling 
Method Preparation 
Stabilizer Particle size (nm) PI Zeta Potential (mV)
PVP K40 
H 666.0  28.4 0.118  0.022 -19.29  0.85 
M 707.6  13.3 0.132  0.027 -23.35  0.67 
L 679.6  23.5 0.103  0.032 -23.60  1.05 
PVA 
H 417.5  27.7 0.176  0.050 -25.20  1.06 
M 412.0  32.1 0.154  0.011 -23.52  0.25 
L - - - 
F-68 
H 793.1  62.8 0.178  0.034 -26.57  0.45 
M 915.7  37.3 0.154  0.011 -27.16  1.25 
L 1034.9  110.9 0.176  0.050 -27.06  0.70 
F-108 
H 301.3  9.5 0.162  0.026 -31.77  1.23 
M 417.9  12.9 0.150  0.014 -25.82  1.29 
L 578.7  10.1 0.198  0.006 -25.45  0.72 
T-80 
H 475.4  12.9 0.112  0.028 -32.64  0.64 
M 481.6  22.2 0.123  0.051 -32.73  0.92 
L 455.4  12.7 0.143  0.034 -28.36  1.56 
PVP K40 / T-80 
(L / L) 
581.9  31.2 0.128  0.049 -25.31  0.88 
PVA / T-80 414.6  10.7 0.164  0.042 -28.81  1.11 
F-68 / T-80 413.5  22.4 0.175  0.053 -32.55  1.78 
F-108 / T-80 366.2  13.2 0.140  0.016 -31.80  0.96 
- : The drug can not be wetted by the stabilizer. 
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4.1.1.2 Influence of Milling Time 
Milling time (1h ~ 48 h) was also screened by fix all other factors. The results were 
shown as Figure 8. The particle size decreased with time by wet milling. After 24 h, the 
mean particle size reached a plateau. Therefore, 24 h was selected as the fixed milling 
time for further studies. 
However, it is premature to draw any conclusion from this preliminary screening data. 
Nevertheless, this step is necessary to focus on relevant variables as quantitative factors 
for further optimization using systematic CCD approach. 
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Figure 8 Dependent of Particle Size (nm) on the Milling Time (h), (n=3). 
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4.1.2. Central Composite Design (CCD)  
In CCD study, particle size and zeta potential were considered as the responses of our 
nanosuspensions. This is because particle size influences not only the bio-distribution 
but also cellular uptake efficiency of nanosuspensions (Jani P et al. 1990). Zeta potential 
reflects the stability of colloidal drug delivery systems, such as nanosuspension. The 
concentration of CZ48, T-80/CZ48 ratio, and F-108/CZ48 ratio were chosen as the 
variables, since they were important factors affecting the particle size and zeta potential, 
as discussed above.  
According to CCD design (Table 3), nanosuspensions were prepared with the three 
factors (at five different levels) which were indicated for each experimental run. The 
experiments at the center points at (0, 0, 0) (n=6) were performed to estimate the 
coefficient of variation (or reproducibility of experiment), which was less than 5%.  
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Table 3 Levels of Critical Influencing Factors and Coded Correspondent 
Values 
Factor 
Level 
- -1 0 1 + 
X1 (CZ48 concentration, wt%) 2 4 6 8 10 
X2 (T-80/CZ48 ratio) 0.02:1 0.22:1 0.51:1 0.80:1 1:1 
X3 (F-108/CZ48 ratio) 0.02:1 0.22:1 0.51:1 0.80:1 1:1 
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Factor levels of each experimental run and values of each nanosuspension properties 
were shown in Table 4. The particle size ranged from 215 to 484 nm (~ 2-fold), indicating 
that with a fine control of the selected factors, nanosuspensions of the optimum particle 
size could be acquired. The obtained data were fitted to the quadratic model (Eqation 1) 
to describe the relationships between the critical influencing factors and responses. 
The following second-order polynomial equations of particle size (Y1) and zeta potential 
(Y2) were generated from the statistical analysis using the quadratic model: 
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The quadratic model was significant with F values of 148 and 79.9 (p < 0.0001), 
respectively, for particle size and zeta potential, which indicated that response variables 
of particle size and zetapotential Y were significantly related to the three of selected X 
variables. Moreover, the high regression coefficients (R2) of these equations, 0.959 and 
0.895, indicated a good correlation between the selected factors and resulting responses. 
The results were shown as Table 5. 
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Among the three factors, CZ48 concentration and F-108/CZ48 ratio had considerable 
impacts on the mean particle size with a p value less than 0.05, but T-80/CZ48 ratio did 
not. This might be due to the fact that T-80 only played a role as a wetting agent in the 
formulation; therefore, its effect on particle size is minimal. There was no correlation 
between seleted factors and PI. 
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Table 4 Experimental Responses and Results of CCD 
Formulation 
NO. (X1, X2, X3) 
Y1: Particle size 
(nm) Y2: PI 
Y3: Zeta potential 
(mV) 
1 (+1, +1, +1) 409.60 0.076 -11.20 
2 (+1, +1, -1) 465.30 0.160 -13.79 
3 (+1, -1, +1) 304.03 0.143 -28.25 
4 (+1, -1, -1) 394.87 0.171 -28.40 
5 (-1, +1, +1) 251.00 0.114 -23.00 
6 (-1, +1, -1) 269.70 0.098 -38.25 
7 (-1, -1, +1) 273.07 0.180 -17.00 
8 (-1, -1, -1) 217.90 0.130 -21.18 
9 (+α, 0, 0) 483.50 0.146 -24.40 
10 (-α, 0, 0) 215.03 0.175 -23.62 
11 (0, +α, 0) 286.20 0.122 -26.02 
12 (0, -α, 0) 242.33 0.149 -28.98 
13 (0, 0, +α) 298.03 0.143 -31.24 
14 (0, 0, -α) 294.70 0.142 -30.75 
15 (0, 0, 0) 221.90 0.159 -31.80 
16 (0, 0, 0) 223.0 0.110 -27.46 
17 (0, 0, 0) 220.9 0.124 -28.45 
18 (0, 0, 0) 213.8 0.106 -28.22 
19 (0, 0, 0) 218.5 0.138 -27.81 
20 (0, 0, 0) 225.4 0.114 -27.21 
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Table 5 Summary of CCD Fitting Parameters 
Regression Coefficient 
Y1 (Particle Size, nm)
Y2 (PI)
Y3 (Zeta Potential, mV)
Estimate p-level Estimate p-level 
b0 535.338 0.006 
N/A 
14.644 0.152 
b1 -101.260 0.005 -9.682 0.012 
b2 -2.776 0.934 -0.952 0.0001 
b3 -2.705 0.010 0.140 0.214 
b4 7.661 0.002 0.418 0.085 
b5 0.018 0.423 0.002 0.621 
b6 0.031 0.055 -0.001 0.269 
b7 0.617 0.049 0.118 0.0001 
b8 -0.027 0.768 0.003 0.168 
b9 0.166 0.313 -0.036 0.091 
F value (p<0.0001) 148  79.9 
R2 0.959  0.895 
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The dependence of particle size on the drug and F-108 concentration was plotted and 
shown in Figure 9, based on the regression equation (Equation 7) by fixing T-80/CZ48 
ratio at 0.1:1. The minimum particle size of 190 nm could be achieved by operating the 
experiment under the following conditions: CZ48 concentration (X1) = 5.9 wt%, T-
80/CZ48 ratio (X2) = 0.1:1 (i.e. 0.59 wt%: 5.9 wt%), F-108/CZ48 ratio (X3) = 0.28:1 (i.e. 
1.28 wt%: 5.9 wt%). 
The dependence of zeta potential on the concentration of CZ48 and F-108/CZ48 ratio 
was also established (Figure 10), based on the regression Equation 8. The zeta potential 
value for a stable nanosuspension requires in the range of -15 to -35 mV. No minimum 
zeta potential value can be achieved. Moreover, the zeta potential values of the 
nanosuspensions, prepared by the optimized experimental conditions by particle size 
model, were all in the stable range. Therefore, the experimental conditions optimized by 
particle size model have been utilized empirically for the preparation of CZ48 
nanosuspensions for further studies.  
The model was proven to be valid since a fine agreement with < 3% of bias existed 
between the predicted and observed values (Table 6). Particle size, PI and Zeta 
potential were 197 ± 7 nm, - 26.5 ± 0.9 mV, and 0.11 ± 0.03, respectively. 
To obtain a larger particle size nanosuspension (around 600 nm), the milling time was 
reduced from 24 hours to 2 hours by fixing the nanosuspension composition as the 
optimized formulation of 200 nm.  
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Figure 9 Surface Response Plot for Particle Size 
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Figure 10 Surface Response Plot for Zeta Potential 
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Table 6 Predicted Values and Experimental Results of CZ48 Nanosuspensions 
Prepared under the Optimum Conditions (n=6) 
Response Predicted value Experimental value  Bias (%)
Y1, particle size (nm) 190 197 ± 7 2.1 
Y2, zeta potential (mV) -25.8 -26.5 ± 0.9 2.7 
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4.1.3. CZ48 Nanosuspension Characterization 
Two CZ48 nanosuspensions were developed by using wet milling technique where the 
drug was mixed with surfactants and ground in-between the sliding glass beads. The 
sizes of the nanosuspensions were about 200 nm (NS-S) and 600 nm (NS-L), 
respectively, depending the milling time. The single distribution population of the 
nanosuspensions indicated a narrow distribution of the particles diameter shown as 
Figure 11. The PI values of NS-S and NS-L were around 0.11 and 0.12, respectively, 
and they were considered within the stable range of nanosuspensions. In addition, the 
two nanosuspensions had similar negative zeta potential value of -26.5 ± 0.9 mV, and -
27.9 ± 0.8 mV, respectively (Table 7).  
4.1.4. CZ48 Nanosuspension Stability 
The stability of the nanosuspensions was monitored for over 6 months by evaluating the 
size, PI and zeta potential of the formulations stored at 4 C. The nanosuspensions were 
measured for the size of the fresh preparation (Day 0) and then on selected days as 
stored at 4 oC. No apparent changes were observed in sizes and size distributions. The 
physical stability could be attributed to the protection resulting from the well selected 
quantites and ratio of the stabilizers, as well as the homogeneous sizes of the 
nanoparticles. Long swinging hydrophilic PEO chains on the particle surface provide an 
excellent steric hindrance, which prevents the particles from aggregation. Moreover, the 
poorly soluble drugs and homogeneous particles hinder the dissolution of smaller 
particles and redeposit to grow into larger particles, i.e. Ostwald ripening. 
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Figure 11 Particle Sizes Distribution [Intensity (%)] of (a) NS-S and (b) NS-L 
a. 
b.
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Table 7 Physical Properties of CZ48 Nanosuspensions 
Nanosuspensions Particle Size (nm) PI  Zeta Potential (mV) 
NS-S 197 ± 7 0.11 ± 0.03 -26.5 ±0.9 
NS-L 589 ± 22 0.12 ± 0.03 -27.9 ±0.8 
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4.1.5. In-vitro Drug Release Study 
4.1.5.1 HPLC Assay for Simultaneous Quantifications of CZ48 and CPT in 
Aqueous Solution 
The isocratic HPLC assay (Li XH, 2004) was adopted for simultaneous quantifications of 
CZ48 and CPT in aqueous solution, and CZ44 was used as IS. The assay was linear in 
the range of 12.5 ~ 200 ng/ml for both CZ48 and CPT. The CPT, CZ44 and CZ48 peaks 
were observed at the retention times of 5.03, 7.07 and 9.69 min, respectively (Figure 12 
& Table 8). The assay was validated with the within-day variability (n = 3) of 1.82 and 
1.59% for CZ48 and CPT, respectively, and the between-day variability (n = 6) of 2.52 
and 2.30% for CZ48 and CPT, respectively (Table 9). Calibration curves for CZ48 and 
CPT were established in aqueous solution (Figure 13).  
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Figure 12 HPLC Chromatograms of (a) Blank Aqueous Solution, and (b) CZ48, 
and CPT (12.5 ng/ml) in Aqueous Solution  
 
a. 
b.
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Table 8 HPLC Chromatogram Peak Identifications for CZ48, CPT, and CZ44 (IS) 
Peak No. Compound Retention Time (min) 
1 CPT-L 5.03 
2 CZ44 (Internal Standard, 20 ng/ml) 7.07 
3 CZ48-L 9.69 
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Figure 13 Calibration Curves for CZ48 and CPT in Aqueous Solution 
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Table 9 Linearity of HPLC Calibration Curves for CZ48 and CPT in Aqueous 
Solution 
Parameters CZ48 CPT 
Conc. Range (ng/ml)         12.5 ~ 200 
Slope 0.09 0.14 
Intercept 0.12 0.15 
R2 (correlation coefficient) 0.999 0.999 
Within-day variability (%), n = 3 1.82 1.59 
Between-day variability (%), n = 6 2.52 2.30 
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4.1.5.2 In-vitro Release of CZ48 from Cosolvent and Two Nanosuspensions 
(NS-S, and NS-L) in PBS (n=3) 
In-vitro release of CZ48 from cosolvent, and nanosuspensions with different particle 
sizes (NS-S and NS-L) were evaluated in PBS at 37 C. Due to the low water solubility 
of CZ48, 0.2 wt% T-80 was added in the PBS solution to maintain the sink condition.  
The kinetics of CZ48 release were characterized by fitting with the equations of 1st-order, 
Higuchi, Peppas, Hixson-Crowell, and Weibull models, respectively, with cumulative 
release of CZ48 (Figure 14). The coefficient of determination was the criterion for the 
goodness of fit of the model to the data. Table 10 shows the fit criteria of the kinetic 
equations to the cumulative release of CZ48 from cosolvent, NS-S, and NS-L in PBS, 
respectively. Equations of 1st-order and Weibull had the best fit to the CZ48 cosolvent 
profile compared to the other models, but no significant difference between 1st-order and 
Weibull kinetics. All equations have equally good fit to the two CZ48 nanosuspensions. 
Based on the “parsimony principle of modeling”, the simplest 1st -order release kinetic 
model was selected to derive the release kinetic parameter, initial release rate, for all of 
the three formulations (Figure 15).  
The initial release rate of CZ48 from nanosuspensions (about 30% /h) was significant 
slower compared to that from cosolvent (84.60 ± 2.76 %/h) (Table 11). Between CZ48 
nanosuspensions of two different particle sizes, the initial release rate of CZ48 from 
larger size, NS-L, was significantly slower than that from the small-sized 
nanosuspension, NS-S at P < 0.05. The mean values of the initial release rate were 
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30.72 ± 3.72, and 21.36 ± 1.92 %/h, respectively. After 6 h, a complete release (> 98 %) 
was observed for all formulations.  
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Figure 14 Release Profiles of CZ48 Cosolvent and Nanosuspensions of Different 
Sizes in PBS at 37 C (n=3). 
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Table 10 Release Kinetics Criteria for CZ48 Cosolvent, NS-S, and NS-L in PBS (n=3) 
Release Kinetic Model
Cosolvent NS-S NS-L 
R2adjusted MSEroot AIC R2adjusted MSEroot AIC R2adjusted MSEroot AIC
1st-order 0.973 5.16 50.0 0.968 5.99 52.7 0.936 7.85 57.3
Higuchi 0.670 18.5 73.2 0.946 7.84 57.7 0.907 9.66 61.5
Peppas 0.829 13.3 68.0 0.946 7.72 58.0 0.952 6.25 53.0
Hixson-Crowell 0.820 13.6 67.7 0.975 5.21 50.1 0.947 6.89 54.0
Weibull 0.983 4.17 47.7 0.980 4.67 49.3 0.956 6.02 51.8
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Figure 15 1st-order Release Kinetics from (a) CZ48 Cosolvent, (b) NS-S, and (c) 
NS-L in PBS. 
a. 
b. 
c. 
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Table 11 1st-order Release Kinetics parameters for CZ48 Cosolvent, NS-S, and 
NS-L in PBS (n=3) 
Formulation Extent of Release ( %/6h ) 1st-Order Release Rate Constant k (%/h)
Cosolvent 98.52 ± 8.40 84.60 ± 2.76 
NS-S 98.40 ± 2.08 30.72 ± 3.72 * 
NS-L 99.68 ± 1.99 21.36 ± 1.92 * # 
Note: 
* p < 0.05 compared to that of cosolvent 
# p < 0.05 compared to that of NS-S 
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4.1.5.3 In-vitro Release of CZ48 from Cosolvent and Two Nanosuspensions 
(NS-S, and NS-L) in Human Plasma (n=3) 
In vitro release of CZ48 from cosolvent and the nanosuspensions with different particle 
sizes were also evaluated in human plasma at 37 C. Different from the CZ48 release 
study in PBS, 0.5 ml of human plasma mixed with CZ48 different formulations, 
respectively, were placed inside of dialysis bags. Similar to the release studies in PBS, 
0.2 wt% T-80 was also added to the release media to maintain the condition. The 
release profiles were biphasic with an initial rapid release up to 2 h followed by a slow 
phase afterwards (Figure 16). The kinetics of CZ48 dissolution profiles were also 
characterized by fitting different equations. There was no single equation that had best fit 
to the profile compared to the other equations, because there was no significant 
difference among the fit to the release profiles to the kinetic equations (Table 12). Similar 
as the formulations dissolution in PBS, the 1st-order kinetic could adequately describe 
the release profiles (Figure 17). 
Comparing the initial release rates of CZ48 from different formulations in human plasma, 
CZ48 nanosuspensions exhibited much slower initial release rates (0.60 %/h) than that 
of the cosolvent formulation (6.48 %/h) (Table 13). No statistical difference in the initial 
release rates was found between NS-S and NS-L. In addition, CZ 48 nanosuspensions 
showed a much lower extent of release (<40 % in 48 h) than that of the cosolvent with a 
complete release, 99% was observes at about 28 h. The extent of release of CZ48 
nanosuspensions in human plasma was less than that in PBS by 60 %. This lower 
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extent can be explained by the strong binding of CZ48 to plasma protein inside the bag 
that yielded less available free CZ48 to be released to the media. CZ48 has a high 
plasma protein binding of ~ 82% (Pfuma E, 2009). 
CZ48 in nanosuspensions exhibited sustained release characteristics when compared to 
cosolvent and this may be attributed to the fact that the solid status of CZ48 in 
nanosuspensions. This sustained release characteristics would be an advantage in 
cancer treatment since CZ48 levels in the systemic circulation would be sustained and 
yielded a prolonged exposure of CZ48 to cancer cells. In this way, the exposure of the 
active form of CPT to the cancer cells may also be increased and which is desirable.
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Figure 16 Release Profiles of CZ48 Cosolvent and Nanosuspensions of Different 
Sizes in Human Plasma at 37 C for (a) 48 h and (b) the First 2 h (n=3). 
 
a. 
b. 
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Table 12 Release Kinetics Criteria for CZ48 Cosolvent, NS-S, and NS-L in PBS (n=3) 
Release Kinetic Model
Cosolvent NS-S NS-L 
R2adjusted MSEroot AIC R2adjusted MSEroot AIC R2adjusted MSEroot AIC
1st-order 0.989 4.27 66.6 0.943 3.10 57.9 0.936 3.19 58.6
Higuchi 0.923 11.1 88.5 0.861 4.84 68.6 0.848 4.93 69.0
Peppas 0.915 11.6 90.4 0.939 3.20 59.6 0.936 3.33 60.5
Hixson-Crowell 0.983 5.23 70.5 0.941 3.16 58.4 0.935 3.23 58.9
Weibull 0.997 2.28 52.1 0.933 3.36 61.4 0.924 3.49 62.3
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Figure 17 1st-order Release Kinetics from (a) CZ48 Cosolvent, (b) NS-S, and (c) 
NS-L in Human Plasma. 
a. 
b. 
c. 
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Table 13 1st-order Release Kinetics Parameters for CZ48 Cosolvent, NS-S, and 
NS-L in Human Plasma (n=3) 
Formulation 
Extent of Release 
( % / 48 h ) 
1st-Order Release Rate Constant k  
(%/h) 
Cosolvent 98.96 ± 2.78 6.48 ± 0.90 
NS-S 36.22 ± 2.49* 0.61 ± 0.12* 
NS-L 34.89 ± 3.09* 0.60 ± 0.06* 
Note: CZ48 Recovery = 98.37 ± 3.55% 
* p < 0.05 compared to that of cosolvent 
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4.2. Plasma Pharmacokinetics and Biodistribution of CZ48 and 
CPT in Rats 
4.2.1. HPLC Assay for Quantitative Analysis of CZ48 and CPT in Rat 
Plasma and Organ Samples 
The reported HPLC assay is a rapid and convenient method for the simutaneous 
quantification of CZ48 and CPT in rat plasma and organs of liver, lungs, kidneys, spleen, 
heart and brain. The developed method was simple, using solvent extraction with 
acetonitrile. CZ44 was chosen as the internal standard for its chemical structure 
similarity to CZ48 and CPT.  
For quantification of CZ48 and CPT in rat plasma, under described conditions (Section 
3.2.6.5), the retention time was 15.13 min, 23.62 min, and 26.07 min for CPT, internal 
standard CZ44, and CZ48, respectively (Table 14). No interference peak was found from 
blank rat plasma (Figure 18). The calibration curves, each containing 6 concentration 
points, were constructed at the linearity range of 0.78 ~ 800 ng/ml with the correlation 
coefficients > 0.999 (Figure 19). The assay was validated with the within-day variability 
(n = 6) of 2.50 and 1.36% for CZ48 and CPT, respectively, and the between-day 
variability (n = 6) of 3.22 and 1.84% for CZ48 and CPT, respectively (Table 15). Plasma 
samples were prepared by precipitation with acetonitrile and the drug recovery of 96% 
for both CZ48 and CPT was achieved.  
 102 
 
Fl
uo
re
sc
en
ce
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
45.00
Minutes
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00
 
15
.1
32
23
.6
23
26
.0
72
Fl
uo
re
sc
en
ce
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
45.00
Minutes
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00
 
Figure 18 HPLC Chromatograms of (a) Rat Blank Plasma Sample and (b) CZ48 
and CPT Spiked Rat Plasma Sample (50 ng/ml) with IS (40 ng/ml) 
 
a. 
b. 
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Table 14 HPLC Chromatogram Peak Identifications for CZ48, CPT, and CZ44 (IS) 
Peak No. Compound Retention Time (min) 
1 CPT-L 15.13 
2 CZ44 (Internal Standard, 20 ng/ml) 23.62 
3 CZ48-L 26.07 
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Figure 19 Calibration Curves of CZ48 and CPT in Rat Plasma Samples 
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Table 15 Linearity of HPLC Calibration Curves for CZ48 and CPT in Rat Plasma 
Samples 
Parameters CZ48 CPT 
Conc. Range (ng/ml) 0.78 ~ 800 
Slope 0.0201 0.0170 
Intercept 0.0001 0.1036 
R2 (correlation coefficient) 0.9999 0.9995 
Within-day variability (%), n = 3 2.50 1.36 
Between-day variability (%), n = 6 3.22 1.84 
Extraction Recovery (%)  96 
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For quantification of CZ48 and CPT in rat six organs, heart, liver, spleen, lung, kidney 
and brain, the analysis was also under the described conditions (Section 3.2.6.5). The 
HPLC chromatograms for each organ were shown, and no interference peak was found 
from individual six blank organs (Figure 20~ Figure 25). The calibration curves, each 
containing 6 concentration points, were constructed at the linearity range of 0.78 ~ 800 
ng/ml with the correlation coefficients > 0.999 for all organs (Figure 26).  
The assay was validated for each organ with the within-day variability (n = 3) of 1.01 ~ 
5.62% and 1.30 ~ 5.76% for CZ48 and CPT, respectively, and the between-day 
variability (n = 6) of 2.32 ~ 6.61% and 1.85 ~ 5.92% for CZ48 and CPT, respectively 
(Table 16). The recoveries of CZ48 and CPT ranged from 83.64 to 98.97%. All of these 
recoveries were acceptable. The linear regression equations of peak area ratios (Y) 
versus concentrations were used to determine CZ48 and CPT concentrations in 
respective organ samples for the biodistribution studies in rats.  
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Figure 20 HPLC Chromatograms of CZ48 and CPT in Rat (a) Blank Heart Sample 
and (b) Spiked Heart Sample at 50 ng/ml (CZ44, 40 ng/ml) 
a. 
b. 
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Figure 21 HPLC Chromatograms of CZ48 and CPT in Rat (a) Blank Liver Sample 
and (b) Spiked Liver Sample at 50 ng/ml (CZ44, 40 ng/ml) 
 
a. 
b. 
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Figure 22 HPLC Chromatograms of CZ48 and CPT in Rat (a) Blank Spleen 
Sample and (b) Spiked Spleen Sample at 50 ng/ml (CZ44, 40 ng/ml) 
a. 
b. 
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Figure 23 HPLC Chromatograms of CZ48 and CPT in Rat (a) Blank Lung Sample 
and (b) Spiked Lung Sample at 50 ng/ml (CZ44, 40 ng/ml) 
 
a. 
b. 
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Figure 24 HPLC Chromatograms of CZ48 and CPT in Rat (a) Blank Kidney 
Sample and (b) Spiked Kidney Sample at 50 ng/ml (CZ44, 40 ng/ml) 
 
a. 
b. 
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Figure 25 HPLC Chromatograms of CZ48 and CPT in Rat (a) Blank Brain Sample 
and (b) Spiked Brain Sample at 50 ng/ml (CZ44, 40 ng/ml) 
a. 
b. 
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Figure 26  Calibration Curves of CZ48 and CPT in Rat (a) Heart, (b) Liver, (c) 
Spleen, (d) Lung, (e) Kidney, (f) Brain Samples 
 
a. 
b. 
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Figure 26  Calibration Curves of CZ48 and CPT in Rat (a) Heart, (b) Liver, (c) 
Spleen, (d) Lung, (e) Kidney, (f) Brain Samples (Cont’s) 
c. 
d. 
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Figure 26 Calibration Curves of CZ48 and CPT in Rat (a) Heart, (b) Liver, (c) 
Spleen, (d) Lung, (e) Kidney, (f) Brain Samples (Cont’s)
e. 
f. 
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Table 16 Calibration Curve Parameters for CZ48 and CPT in Rat Organ Samples 
Parameters 
Heart Liver Spleen Lung Kidney Brain 
CZ48 CPT CZ48 CPT CZ48 CPT CZ48 CPT CZ48 CPT CZ48 CPT 
Conc. Range (ng/ml) 0.78 ~ 800 
Slope 0.0220 0.0350 0.0209 0.0338 0.019 0.0309 0.0216 0.035 0.0209 0.0327 0.0238 0.0358
Intercept -0.0165 0.2293 -0.046 0.0158 -0.0564 -0.0111 -0.0551 0.0208 0.0733 0.0998 0.0538 -0.0118
R2 
(correlation coefficient) 
1.0000 0.9999 0.9998 0.9998 0.9997 0.9997 0.9998 0.9998 0.9994 1.0000 0.9998 1.0000
Within-day variability (%), 
n = 3 
1.58 1.30 1.01 2.25 2.34 2.83 5.62 5.76 2.55 3.17 3.79 3.01 
Between-day variability (%), 
n = 6 
2.66 1.85 2.32 4.11 3.49 3.74 6.61 5.92 4.30 3.96 4.05 3.88 
Extraction Recovery (%) 96.86 93.62 97.56 90.56 98.97 95.07 90.18 83.64 98.91 95.28 91.21 94.68 
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4.2.2. Plasma Pharmacokinetics of CZ48 Cosolvent and 
Nanosuspensions (NS-S, and NS-L) in Rats 
Plasma pharmacokinetics of CZ48 cosolvent and nanosuspensions (NS-S and NS-L) 
were studied in SD rats at a dose of 5 mg/kg, 25 mg/kg and 25mg/kg, respectively. The 
objective of the pharmacokinetic studies was to demonstrate any favorable 
pharmacokinetics of sustaining levels of CZ48 in plasma and consequently, those of the 
active moiety, CPT, which may offer potential therapeutic benefit from the 
nanosuspension formulations. 
The formulations were given by i.v. injection and blood samples were collected for CZ48 
and CPT quantifications by the validated HPLC assay. The mean concentration 
normalized by dose-time profiles of CZ48 and CPT were constructed (Figure 27). 
Compartmental modeling was used to desire the pharmacokinetic parameters of CZ48 
and CPT for each rat (WinNonlin ver. 3.3). Then, each parameter was presented as 
mean value with the standard deviation, and statistical analysis was also performed 
(Table 17 & Table 18). 
For all of these three formulations, the CZ48 plasma concentrations declined rapidly 
after the injection. After a rapid decline, CZ48 was slowly removed from the central 
compartment by nanosuspensions administration; however, CZ48 from cosolvent was 
undetectable 4 hours post dose. Similarly, the mean plasma concentrations of CPT 
converted from CZ48 nanosuspensions increased consistently to the peak 
concentrations and yielded sustained levels of CPT in the blood circulation for more than 
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24 h (NS-S) or 10 h (NS-L) compared with cosolvent of which the CPT was undetectable 
after 4 h (Figure 27). The plasma profiles of CPT were best described as 1-
compartmental and 2-compartmental models from cosolvent and nanosuspensions, 
respectively. 
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Figure 27 Mean Plasma Concentration Normalized by Dose verses Time Curves 
of CZ48 and CPT, after i.v. Administration of CZ48 Cosolvent (5 mg/kg), 
NS-200 nm (25 mg/kg) and NS-600 nm in SD rats (n = 6). 
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Table 17 Pharmacokinetic Parameters of CZ48 from Cosolvent, NS-S, and NS-L 
in SD Rat Plasma after i.v. Administration (n = 6). 
Parameters Unit Cosolvent (5 mg/kg) NS-S (25 mg/kg) NS-L (25 mg/kg) 
A nM  65569.77 ± 19407.75 11484.35 ± 2046.37# 
α h-1  51.49 ± 26.31 38.94 ± 7.35 
B nM  3774.39 ± 451.52 2986.89 ± 735.92# 
β h-1  0.99 ± 0.35 1.00 ± 0.71 
C nM  236.06 ± 93.78 294.98 ± 142.51 
 h-1  0.02 ± 0.01 0.10 ± 0.04# 
k10 h-1 1.44 ± 0.52 4.78 ± 2.30* 2.31 ± 1.21*# 
k12 h-1  35.87 ± 26.31 26.64 ± 17.16 
k21 h-1  3.86 ± 2.63 9.37 ± 4.23# 
k13 h-1  7.93 ± 2.49 1.54 ± 0.32# 
k31 h-1  0.07 ± 0.03 0.17 ± 0.05# 
t1/2α h  0.01 ± 0.00 0.02 ± 0.01# 
t1/2β h  0.70 ± 0.24 0.70 ± 0.42 
t1/2 h 0.48 ± 0.13 27.74 ± 10.34* 7.27 ± 1.20* 
C0/Dose nM/(mg/kg) 991.38 ± 316.52 738.21 ± 283.14 590.65 ± 110.98* 
V1 L/kg 2.49 ± 1.06 0.89 ± 0.15* 4.18 ± 1.50*# 
CL1 L/kg*h 3.59 ± 1.02 4.25 ± 1.19* 9.67 ± 1.86*# 
V2 L/kg  8.26 ± 2.68 11.89 ± 3.20# 
CL2 L/kg*h  31.85 ± 10.85 111.46 ± 39.61# 
V3 L/kg  102.35 ± 31.66 37.70 ± 16.42# 
CL3 L/kg*h  7.04 ± 1.45 6.44 ± 1.61 
AUC0-t/Dose nM*h/(mg/kg) 686.12 ± 135.15 374.51 ± 55.49* 242.89 ± 46.44*# 
AUC0-/Dose nM*h/(mg/kg) 688.18 ± 146.21 581.94 ± 71.54 255.47 ± 44.71*
# 
F   0.85 0.37 
AUMC nM*h2 2388.55 ± 451.24 381937.68 ± 23218.42* 35500.06 ± 8042.37*#
MRT h 0.69 ± 0.35 26.25 ± 10.34* 5.56 ± 0.80*# 
Vss L/kg 2.49 ± 1.64 111.49 ± 32.00* 53.77 ± 21.61*# 
Note: * p < 0.05, compared to that of cosolvent; # p < 0.05, compare to that of NS-S 
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Table 18 Pharmacokinetic Parameters of CPT from Cosolvent, NS-S, and NS-L 
in SD Rat Plasma after i.v. Administration (n = 6). 
Parameters Unit Cosolvent (5 mg/kg) NS-S (25 mg/kg) NS-L (25 mg/kg) 
A nM 55.97 ± 14.31 534.44 ± 71.54* 301.76 ± 88.42*# 
α h-1  0.55 ± 0.13 0.58 ± 0.20 
B nM  47.29 ± 17.46 89.40 ± 28.65 
β h-1  0.11 ± 0.03 0.58 ± 0.17# 
ka h-1 7.76 ± 2.86 3.36 ± 0.85* 3.22 ± 0.61* 
k10 h-1 1.13 ± 0.32 0.40 ± 0.07* 0.58 ± 0.20* 
k12 h-1  0.11 ± 0.03  
k21 h-1  0.15 ± 0.06  
t1/2α h  1.27 ± 0.39  
t1/2β h 0.62 ± 0.16 6.34 ± 1.45* 1.19 ± 0.35*# 
t1/2ka h 0.09 ± 0.05 0.21 ± 0.17 0.22 ± 0.10 
V1 L/kg 299.94 ± 55.49 145.44 ± 83.43* 290.44 ± 59.44# 
CL1 L/kg*h 337.71 ± 73.10 57.88 ± 21.16* 169.61 ± 35.22*# 
V2 L/kg  103.78 ± 31.65  
CL2 L/kg*h  15.53 ± 2.06  
Tmax h 0.29 ± 0.06 0.67 ± 0.10* 0.65 ± 0.15* 
Cmax/Dose nM/(mg/kg) 6.90 ± 1.45 14.14 ± 3.82* 6.77 ± 1.68 
AUC0-t/Dose nM*h/(mg/kg) 8.39 ± 2.86 48.33 ± 17.46* 16.73 ± 4.25*# 
AUC0-/Dose nM*h/(mg/kg) 8.50 ± 3.54 49.59 ± 17.54* 16.92 ± 2.06*
# 
F   5.83 1.99 
AUMC nM*h2 43.22 ± 7.15 5707.35 ± 1502.04* 855.76 ± 202.98*#
MRT h 1.02 ± 0.32 4.60 ± 0.72* 2.02 ± 0.55*# 
Vss L/kg 299.94 ± 55.49 249.22 ± 96.52 290.44 ± 59.44 
Note: * p < 0.05, compared to that of cosolvent; # p < 0.05, compare to that of NS-S 
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4.2.2.1 Comparative Pharmacokinetics of CZ48 in Rats Following i.v. 
Administration of Cosolvent and Nanosuspensions (NS-S, and NS-L) 
of CZ48 
The pharmacokinetic performances of CZ48 from NS-S and NS-L were significantly 
different from that of cosolvent with half-life of 60 and 15 fold longer (27.74 ± 10.34 h 
and 7.27 ± 1.20 h vs. 0.48 ± 0.13 h). The AUC0- normalized by dose of CZ48 NS-S and 
NS-L were 85% and 37% of that of CZ48 cosolvent, respectively (581.94 ± 71.54 
nM*h/(mg/kg), 255.47 ± 44.71 nM*h/(mg/kg) vs. 688.18 ± 146.21 nM*h/(mg/kg)). CZ48 
from nanosuspensions were widely distributed to other tissues besides plasma, and had 
significantly larger Vss compared to that from cosolvent (111.49 ± 32.00 L/kg and 53.77 ± 
21.61 L/kg for NS-S and NS-L, respectively vs. 2.49 ± 1.64 L/kg for cosolvent). 
4.2.2.2 Comparative Pharmacokinetics of CPT Following i.v. Administration 
of Cosolvent and Nanosuspensions (NS-S, and NS-L) of CZ48 in 
Rats 
The dose-normalized AUC0-∞ values for NS-S and NS-L were significantly higher than 
that of cosolvent (48.33 ± 17.54 nM*h/(mg/kg), 16.92 ± 2.06 nM*h/(mg/kg) vs. 8.50 ± 
3.54 nM*h/(mg/kg)). Nanosuspensions not only yielded larger systemic exposures of 
CPT, but also significantly longer half-lives compared to that from cosolvent, ~10.23 
times longer for NS-S (6.34 ± 1.45 vs. 0.62 ± 0.16 h), and ~1.92 times longer for NS-L 
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(1.19 ± 0.35 vs. 0.62 ± 0.16 h) at p < 0.05. The Vss of CPT were comparable among 
groups of cosolvent, NS-S and NS-L.  
4.2.3. Organ Distribution of CZ48 and Metabolite, CPT, from 
Cosolvent and Nanosuspensions (NS-S, and NS-L) in Rats (n=4) 
The biodistribution study in rats was comparatively evaluated for the CZ48 cosolvent, 
NS-S and NS-L. Different tissue distribution patterns of CZ48 and CPT from cosolvent, 
NS-S and NS-L were observed (Figure 28 ~ Figure 30) which were anticipated based on 
their plasma pharmacokinetic profiles. The mean organ parameters were derived from 
the mean concentration-time profiles for each formulation by WinNonlin (Table 19 ~ 
Table 21).  
4.2.3.1 Organ Distributions of CZ48 and CPT from Cosolvent in Rats 
CZ48 from cosolvent was cleared within 8 h in most of the organs with half-lives less 
than 1 hour (Table 19), except in lung and heart which can be detected more than 24 h 
(Figure 28). The observation of high substantial distribution of CZ48 in lung from 
cosolvent was not anticipated. This might be due to the CZ48 precipitation from the 
cosolvent. Similarly, the CPT concentrations in all the major organs and in plasma 
declined rapidly after reaching the peak concentrations (Figure 28). 
CZ48 in cosolvent yielded the highest exposure in lung with and AUC0-/Dose of 
25856.53 (ng/g*h)/(mg/kg), followed by liver of 721.49 (ng/g*h)/(mg/kg), kidney of 653.57 
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(ng/g*h)/(mg/kg), and spleen of 603.99 (ng/g*h)/(mg/kg) (Table 19). The elimination half-
lives were all about 1 hour for heart, liver, spleen, lung, kidney, and brain (0.70 h, 1.14 h, 
0.81 h, 1.05 h, 0.86 h, and 0.59 h, respectively). But only a very small portion of CZ48 in 
lung was transformed to CPT with a small AUC0-/Dose of 35.79 (ng/g*h)/(mg/kg) and 
low Cmax/Dose 19.09 (ng/g)/(mg/kg) (Table 19).  
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Figure 28 Organ Distribution Profiles of CZ48 and CPT from Cosolvent in Rats 
(n=4) 
Note: The concentration unit for CZ48 and CPT in plasma is (ng/ml)/(mg/kg). 
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Table 19 CZ48 and CPT Organ Distribution Parameters from Cosolvent in Rats after i.v. Administration 
(n=4) 
Parameters Unit 
Cosolvent 
Heart Liver Spleen Lung Kidney Brain Plasma
CZ48 
AUC0-/Dose (ng/g*h)/(mg/kg) 447.95 721.49 603.99 25856.53 653.57 97.29 278.44
Cmax/Dose (ng/g)/(mg/kg) 339.92 736.54 506.44 12873.34 658.76 133.29 268.94
t1/2 h 3.12 0.78 0.99 1.90 0.60 0.42 0.48 
CPT 
AUC0-/Dose (ng/g*h)/(mg/kg) 15.56 82.74 29.02 35.79 57.34 6.06 2.96 
Cmax/Dose (ng/g)/(mg/kg) 17.96 56.61 26.23 19.09 36.98 7.61 2.39 
t1/2 h 0.70 1.14 0.81 1.05 0.86 0.59 0.63 
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4.2.3.2 Organ Distributions of CZ48 and CPT from NS-S in Rats 
For all the organs, the CZ48 concentrations declined rapidly after CZ48 NS-S injection, 
and then followed by a slow elimination with long half-lives of 11.18 h for heart, 7.88 h 
for liver, 1.76 h for spleen, 5.37 h for lung, 16.50 h for kidney, 5.13 h for brain (Table 19). 
The CZ48 could still be detected 24 h post injection in all the organs, except in brain 
(Figure 28). The RES rich organs obtained more CZ48 particles with the highest AUC0-
/Dose of 38697.93 (ng/g*h)/(mg/kg) in spleen, followed by 26501.08 (ng/g*h)/(mg/kg) in 
liver, and 3299.46 (ng/g*h)/(mg/kg) in lung (Table 19).  
Similar to CZ48, CPT exposures were high in RES rich organs, and yielded the highest 
exposure in liver with the AUC0-/Dose of 58.26 (ng/g*h)/(mg/kg), followed by spleen of 
35.04 (ng/g*h)/(mg/kg), and lung of 15.60 (ng/g*h)/(mg/kg). Except brain heart and 
kidney, CPT can be retained more than 24 hours in all the other organs (Figure 28).  
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Figure 29 Organ Distribution Profiles of CZ48 and CPT from NS-S in Rats (n=4) 
Note: The concentration unit for CZ48 and CPT in plasma is (ng/ml)/(mg/kg). 
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Table 20 CZ48 and CPT Organ Distribution Parameters from NS-S in Rats after i.v. Administration (n=4) 
Parameters Unit 
NS-S 
Heart Liver Spleen Lung Kidney Brain Plasma
CZ48 
AUC0-/Dose (ng/g*h)/(mg/kg) 701.60 26501.08 38697.93 3299.46 330.37 30.78 235.45
Cmax/Dose (ng/g)/(mg/kg) 310.74 8867.73 13515.22 3242.30 120.50 18.31 50.70 
t1/2 h 11.18 7.88 1.76 5.37 16.50 5.13 13.33 
CPT 
AUC0-/Dose (ng/g*h)/(mg/kg) 8.15 58.26 35.04 15.60 15.81 3.08 17.28 
Cmax/Dose (ng/g)/(mg/kg) 3.36 12.65 5.05 4.97 4.88 1.55 4.77 
t1/2 h 1.28 5.59 4.30 4.10 2.48 1.08 3.77 
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4.2.3.3 Organ Distributions of CZ48 and CPT from NS-L in Rats 
Similarly, the CZ48 could still be detected 24 h post injection in all the organs with long 
half-lives of 5.21 h for heart, 8.25 h for liver, 2.88 h for spleen, 7.97 h for lung, 2.57 h for 
kidney, 9.49 h for brain. The RES rich organs obtained more CZ48 particles with the 
highest AUC0-/Dose of 50336.22 (ng/g*h)/(mg/kg) in liver, followed by 35172.84 
(ng/g*h)/(mg/kg) in spleen, and 8221.77 (ng/g*h)/(mg/kg) in lung (Table 19).  
Except heart, CPT could be retained more than 24 hours after CZ48 NS-L injection in all 
the other organs. In liver, CPT showed the highest Cmax/Dose of 23.86 (ng/g)/(mg/kg), 
and AUC0-/Dose of 124.59 (ng/g*h)/(mg/kg) (Table 19).  
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Figure 30 Organ Distribution Profiles of CZ48 and CPT from NS-L in Rats (n=4) 
Note: The concentration unit for CZ48 and CPT in plasma is (ng/ml)/(mg/kg). 
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Table 21 CZ48 and CPT Organ Distribution Parameters from NS-L in Rats after i.v. Administration (n=4) 
Parameters Unit 
NS-L 
Heart Liver Spleen Lung Kidney Brain Plasma
CZ48 
AUC0-/Dose (ng/g*h)/(mg/kg) 619.18 50336.22 35172.84 8221.77 400.85 36.49 103.36
Cmax/Dose (ng/g)/(mg/kg) 276.00 8532.57 10519.72 4120.52 128.89 14.62 42.36 
t1/2 h 5.21 8.25 2.88 7.97 2.57 9.49 3.96 
CPT 
AUC0-/Dose (ng/g*h)/(mg/kg) 7.00 124.59 17.05 12.13 15.69 3.34 6.84 
Cmax/Dose (ng/g)/(mg/kg) 2.87 23.86 2.15 3.12 5.35 1.39 2.44 
t1/2 h 1.44 5.63 7.00 5.11 1.65 4.16 1.95 
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4.2.3.4 Comparative Organ Distributions of CZ48 and CPT Following i.v. 
Administration of Cosolvent and Nanosuspensions (NS-S, and NS-L) 
of CZ48 in Rats 
Based on the areas under the curve normalized by the dose, biodistribution patterns of 
CZ48 nanosuspensions were distinct from those from cosolvent, but followed a similar 
trend between the NS-S and NS-L, with significantly high CZ48 exposures of 3299.46  ~ 
50336.22 (ng/g*h)/(mg/kg) in liver, spleen and lung, due to RES uptake (Table 22). The 
exposure ranking of CZ48 after nanosuspensions administration was Spleen, Liver >> 
Lung >> Heart >> Kidney > Plasma > Brain. CZ48 from cosolvent was relatively evenly 
distributed among organs (difference is within one log scale), except in the lung. One 
possibility of the exception is potential precipitation of CZ48 in the lung and subsequent 
entrapment of the precipitate following tail vein injection. However, the change of 
nanosuspension particle sizes within 200 nm to 600 nm range does not have significant 
effect on the distribution patterns of CZ48. Similar exposure of CPT from all three 
formulations were observed with the exposure ranking of Liver > Spleen, Kidney, Lung > 
Heart, Brain.  
CZ48 from nanosuspensions were eliminated much slowly from all the organs and 
plasma, with longer elimination half-lives of 1.76 h ~ 16.05 h, compared to those from 
cosolvent of 0.42 h ~ 3.12 h, with 2 to 25 times increase (Table 23). More importantly, 
both nanosuspensions provided 2 ~ 9 times prolonged exposures of active CPT in all 6 
major organs (heart, liver, spleen, lung, kidney, and brain) and in plasma, compared to 
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those from cosolvent (Table 23). However, the change of nanosuspension particle sizes 
within 200 nm to 600 nm range does not have significant effects on the half-lives of 
CZ48 and CPT.  
4.2.3.5 Comparative Organ/Plasma Partition Coefficient of CZ48 and CPT 
Following i.v. Administration of Cosolvent and Nanosuspensions 
(NS-S, and NS-L) of CZ48 in Rats 
The organ/plasma partition coefficient (Kp) of CZ48 and CPT for the heart, liver, spleen, 
lung, kidney and brain were derived experimentally from the Organ AUC/Plasma AUC 
ratios toward the end of the study (Figure 31 ~ Figure 33). The Kp values of CZ48 in 
organs from nanosuspensions were several times to hundred times higher than those 
from cosolvent, except in kidney and brain, which may indicate that the nanoparticles 
were easily trapped by heart, liver, spleen, lung. On the contrary, the partition 
coefficients (Kp) of CPT from nanosuspensions were significantly lower in all organs, 
except in spleen. The uptake of CZ48 was in nanosuspension form, while only dissolved 
CZ48 could be converted to CPT and provided the reservoir effect in the organs.  
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Table 22 Exposure (AUC0-t/Dose) of CZ48 and CPT from Cosolvent, NS-S and 
NS-L in Different Organs 
AUC0-/Dose [(ng/g)/(mg/g)] 
Organs
CZ48 CPT 
Cosolvent NS-S NS-L Cosolvent NS-S NS-L 
Heart 447.95 701.60 619.18 15.56 8.15 7.00 
Liver 721.49 26501.08 50336.22 82.74 58.26 124.59 
Spleen 603.99 38697.93 35172.84 29.02 35.04 17.05 
Lung 25856.53 3299.46 8221.77 35.79 15.60 12.13 
Kidney 653.57 330.37 400.85 57.34 15.81 15.69 
Brain 97.29 30.78 36.49 6.06 3.08 3.34 
Plasma 278.44 235.45 103.36 2.96 17.28 6.84 
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Table 23 Half-lives of CZ48 and CPT from Cosolvent, NS-S and NS-L in Different 
Organs 
t1/2 (h) 
Organs 
CZ48 CPT 
Cosolvent NS-S NS-L Cosolvent NS-S NS-L 
Heart 3.12 11.18 5.21 0.70 1.28 1.44 
Liver 0.78 7.88 8.25 1.14 5.59 5.63 
Spleen 0.99 1.76 2.88 0.81 4.30 7.00 
Lung 1.90 5.37 7.97 1.05 4.10 5.11 
Kidney 0.60 16.05 2.57 0.86 2.48 1.65 
Brain 0.42 5.13 9.49 0.59 1.08 4.16 
Plasma 0.48 13.33 3.96 0.63 3.77 1.95 
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Figure 31 Profiles of Partition Coefficient (Kp) of CZ48 and CPT from Cosolvent 
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Figure 32 Profiles of Partition Coefficient (Kp) of CZ48 and CPT from NS-S 
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Figure 33 Profiles of Partition Coefficient (Kp) of CZ48 and CPT from NS-L 
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4.3. Plasma Pharmacokinetics and Biodistribution of CZ48 and 
CPT in Mice 
4.3.1. HPLC Assay for Quantitative Analysis of CZ48 and CPT in Mice 
Plasma and Organ Samples 
For quantifications of CZ48 and CPT in mouse plasma, under described conditions 
(Section 3.2.6.5), the retention time was 15.13 min, 23.62 min, and 26.07 min for CPT, 
internal standard CZ44, and CZ48, respectively. No interference peak was found from 
blank mouse plasma. The calibration curves, each containing 6 concentration points, 
were constructed at the linearity range of 0.78 ~ 800 ng/ml with the correlation 
coefficients > 0.999. The assay was also validated with the within-day variability (n = 6) 
of 3.26 and 1.58% for CZ48 and CPT, respectively, and the between-day variability (n = 
6) of 3.86 and 2.48% for CZ48 and CPT, respectively. Plasma samples were prepared 
by precipitation with acetonitrile and high recoveries of 96% for both CZ48 and CPT drug 
was achieved.  
For quantifications of CZ48 and CPT in mouse six organs, heart, liver, spleen, lung, 
kidney and brain, the analysis was also performed under the described conditions 
(Section 3.2.6.5). No interference peak was found from all six blank organs. The 
calibration curves, each containing 6 concentration points, were also constructed at the 
linearity range of 0.78 ~ 800 ng/ml with the correlation coefficients > 0.999 for all organs.  
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The assay was also validated for each organ with the within-day variability (n = 3) of 1.86 
~ 5.17% and 1.21 ~ 4.56% for CZ48 and CPT, respectively, and the between-day 
variability (n = 6) of 2.43 ~ 6.52% and 1.82 ~ 4.95% for CZ48 and CPT, respectively. 
The recoveries of CZ48 and CPT were ranged from 84.25 to 97.32%. All of these 
recoveries were acceptable according to FDA Guidance for Industry - Bioanalytical 
Method Validation. The linear regression equations of peak area ratios (Y) versus 
concentrations (X) were used to determine CZ48 and CPT concentrations in respective 
organs of biodistribution studies in mice. 
4.3.2. Plasma Pharmacokinetics of CZ48 Cosolvent and 
Nanosuspensions (NS-S, and NS-L) in Mice (n=4) 
Plasma pharmacokinetics for CZ48 and its active metabolite, CPT, from cosolvent and 
nanosuspensions (NS-S and NS-L) in Swiss nude mice have also been studied. 
Different doses of CZ48 cosolvent, and CZ48 nanosuspensions were selected due to the 
toxicity of the cosolvent formulation to mice and for the consistency to the in vivo study in 
rats. The formulations were given by i.v. injection and blood samples were collected for 
CZ48 and CPT quantifications by the HPLC assay. The plasma concentration-time 
profiles were constructed using sparse sampling approach. The mean concentration-
time profiles were generated by calculating the mean concentration at each time point 
from samples collected from four mice that were sacrificed at the given time point as 
described in Section 3.2.7.2.  
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The profiles of nanosuspensions were distinct from that of cosolvent for both CZ48 and 
CPT, especially the slower elimination phase (Figure 34). Compartmental models by 
WinNonlin Professional 3.0 were fitted to the mean plasma concentration profiles to 
derive the pharmacokinetics parameters. The pharmacokinetics parameters were 
presented as the means without the standard deviations (Table 24 & Table 25).  
4.3.2.1 Comparative Pharmacokinetics of CZ48 Following i.v. 
Administration of Cosolvent and Nanosuspensions (NS-S, and NS-L) 
of CZ48 in Mice 
The pharmacokinetic performances of CZ48 from NS-S and NS-L were different from 
those of cosolvent with half-lives of 11 and 8 fold longer (8.00 h and 5.58 h vs. 0.70 h) 
(Table 26). CZ48 from NS-S and NS-L were widely distributed to other organs besides 
plasma, and had larger Vss compared to that from cosolvent (41.12 and 30.61 L/kg vs. 
6.48 L/kg, respectively). At the same time, NS-S and NS-L had lower C0 normalized by 
the dose of CZ48 than that from the cosolvent (122.29 and 172.48 nM/(mg/kg) vs. 
381.66 nM/(mg/kg)). The AUC0-/Dose values of CZ48 were comparable among groups 
of cosolvent, NS-S and NS-L. 
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4.3.2.2 Comparative Pharmacokinetics of CPT Following i.v. Administration 
of Cosolvent and Nanosuspensions (NS-S, and NS-L) of CZ48 in 
Mice 
The dose-normalized AUC0-∞ values for NS-S was higher than those of NS-L and 
cosolvent (19.78 nM*h/(mg/kg), 10.95 nM*h/(mg/kg) vs. 8.29 nM*h/(mg/kg)). NS-S and 
NS-L not only showed larger systemic exposure of CPT, but also longer half-lives 
compared to cosolvent (12.51, and 5.81 h vs. 0.40 h). The Vss of CPT were comparable 
among groups of cosolvent, NS-S and NS-L (Table 26). 
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Figure 34 Mean Plasma Concentration Normalized by Dose verses Time Curves 
of CZ48 and CPT after i.v. Administration of CZ48 Cosolvent (5 mg/kg), 
NS-S (25 mg/kg) and NS-L (25 mg/kg) in Mice (n = 4).  
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Table 24 Pharmacokinetic Parameters of CZ48 from Cosolvent, NS-S, and NS-L 
in Mouse Plasma after i.v. Administration (n = 4).  
Parameters Unit 
Cosolvent NS-S NS-L 
5 mg/kg 25 mg/kg 25 mg/kg 
CZ48 
A nM  2521.58 3774.76 
 h-1  0.52 0.79 
B nM  535.64 537.16 
 h-1  0.09 0.12 
k10 h-1 0.99 0.28 0.48 
k12 h-1  0.17 0.24 
k21 h-1  0.16 0.21 
t1/2 h  1.33 0.87 
t1/2 h 0.70 8.00 5.58 
V1 L/kg 6.48 20.21 14.33 
CL1 L/kg*h 6.41 5.62 6.81 
V2 L/kg 20.91 16.28 
CL2 L/kg*h  3.41 3.38 
C0/Dose nM/(mg/kg) 381.66 122.29 172.48 
AUC0-t/Dose nM*h/(mg/kg) 384.68 352.31 323.98 
AUC0-/Dose nM*h/(mg/kg) 385.70 440.08 362.95 
F   1.14 0.94 
AUMC nM*h2 1948.90 80551.07 40783.45 
MRT h 1.01 7.32 4.49 
Vss L/kg 6.48 41.12 30.61 
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Table 25 Pharmacokinetic Parameters of CPT from Cosolvent, NS-S, and NS-L 
in Mouse Plasma after i.v. Administration (n = 4). 
Parameters Unit 
Cosolvent NS-S NS-L 
5 mg/kg 25 mg/kg 25 mg/kg 
CPT 
A nM 84.19 10732.96 7970.13 
 h-1  1.42 1.33 
B nM  9.25 7.69 
 h-1  0.06 0.12 
ka h-1 11.12 1.49 1.38 
k10 h-1 1.72 0.98 1.07 
k12 h-1  0.42 0.23 
k21 h-1  0.08 0.15 
t1/2 h  0.49 0.52 
t1/2 h 0.40 12.51 5.81 
t1/2ka h 0.06 0.47 0.50 
V1 L/kg 11587.84 1703.65 2814.09 
CL1 L/kg*h 19893.92 1668.12 3015.03 
V2 L/kg  8867.19 4394.96 
CL2 L/kg*h  714.67 652.55 
Tmax h 0.20 0.70 0.75 
Cmax/Dose nM/(mg/kg) 10.12 7.38 4.46 
AUC0-t/Dose nM*h/(mg/kg) 8.24 16.35 10.16 
AUC0-/Dose nM*h/(mg/kg) 8.29 19.78 10.95 
F   2.39 1.32 
AUMC nM*h2 27.88 3466.05 852.25 
MRT h 0.67 7.01 3.11 
Vss L/kg 11587.84 10570.84 7209.05 
 
 
 147 
 
4.3.3. Organ Distributions of CZ48 and Metabolite, CPT, from 
Cosolvent and Nanosuspensions (NS-S, and NS-L) in Mice (n=4) 
The biodistribution study in mice was also comparatively evaluated for the CZ48 from 
cosolvent, NS-S and NS-L. Different organ distribution patterns of CZ48 and CPT among 
cosolvent, NS-S and NS-L were observed (Figure 35 ~ Figure 37). The mean organ 
parameters were derived from the mean concentration-time profiles for each formulation 
by WinNonlin (Table 26 ~ Table 28). The drug concentrations in different organs showed 
similar trends as that in plasma. The profiles of nanosuspensions were distinct from 
those of cosolvent for both CZ48 and CPT, especially the slower elimination phase.  
4.3.3.1 Organ Distributions of CZ48 and CPT from Cosolvent in Mice 
Both CZ48 and CPT can be characterized as one-compartment model.  
The concentrations decreased very fast after CZ48 cosolvent administration with the 
half-lives of about 1 hour (Table 26). The organ peak concentrations were reached 
before the collection at the first time point. CZ48 uptake (Cmax/dose) from the cosolvent 
was comparable among the lung, liver, kidney, spleen and heart (200.65 ~ 543.24 
(ng/g)/(mg/kg)), but lower by the brain, 49.63 (ng/g)/(mg/kg) (Figure 35 & Table 26)). The 
exposure (AUC) normalized by the dose of the lung from CZ48 cosolvent was 1038.38 
(ng*h/g)/(mg/kg), the highest among the organs. The exposures of CZ48 in the liver, and 
kidney were comparable (690.54 and 604.57 (ng*h/g)/(mg/kg)) and higher than those of 
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the heart, spleen and brain (296.14, 282.28 and 59.59 (ng*h/g)/(mg/kg), respectively) 
(Table 26).  
The highest CPT exposure from cosolvent was in the liver followed by kidney, 99.03, 
and 57.25 (ng*h/g)/(mg/kg), respectively. The CPT exposure was comparable in spleen 
and lung (34.34, and 34.18 (ng*h/g)/(mg/kg)). The smallest exposure was in the brain 
(8.25 (ng*h/g)/(mg/kg)). The elimination half-lives were all about 1 hour for heart, liver, 
spleen, lung, kidney, and brain; 0.99 h, 1.17 h, 0.81 h, 0.77 h, 1.48 h, and 0.68 h, 
respectively (Table 26). 
4.3.3.2 Organ Distributions of CZ48 and CPT from NS-S in Mice 
Both CZ48 and CPT can be characterized by two-compartment model.  
The distribution pattern from CZ48 NS-S was different from that of the cosolvent (Figure 
35. The highest uptake was in the liver with the highest Cmax/Dose (5521.13 
(ng/g)/(mg/kg)) followed by the spleen/lung, kidney/heart, and brain; 3230.42/1689.83, 
194.71/148.24, and 9.99 (ng/g)/(mg/kg), respectively. The CZ48 exposures (AUC0-
/Dose) among the organs from NS-S followed the same ranking in patterns of 
Cmax/Dose. The highest CZ48 exposure from NS-S was in the liver followed by spleen 
and lung; 13686.92, 5374.30 and 5374.30 (ng*h/g)/(mg/kg), respectively. The smallest 
exposure from NS-S was in the brain of 34.61 (ng*h/g)/(mg/kg)). The t1/2 of CZ48 in the 
lung was 38.21 h, the longest among the organs. The t1/2 in the heart (8.29 h) was longer 
than that in the brain and kidney (4.45 and 3.20 h). The t1/2 of CZ48 in the liver (1.96 h) 
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was comparable to that in the spleen (1.64 h) which was the shortest among the organs 
(Table 29).  
CPT yielded the highest exposure in liver with the AUC0-/Dose of 191.38 
(ng/g*h)/(mg/kg), followed by kidney of 57.35 (ng/g*h)/(mg/kg), spleen of 48.51 
(ng/g*h)/(mg/kg) and lung of 55.18 (ng/g*h)/(mg/kg). CPT can be retained more than 12 
hours in all the six major organs (Table 29).  
4.3.3.3 Organ Distributions of CZ48 and CPT from NS-L in Mice 
Both CZ48 and CPT can be characterized by two-compartment model.  
The distribution pattern of CZ48 from NS-L was different from that of the cosolvent but 
similar to that of NS-S (Figure 35 & Figure 35). The highest uptake (Cmax/Dose) was 
observed in the liver, 86253.18 (ng/g)/(mg/kg), while the other organs were in the 
following rank: spleen > lung > kidneys > heart > brain (3350.07, 1612.12, 355.41, 
169.97 and 34.14 (ng/g)/(mg/kg), respectively. The liver exposure was the highest 
among the organs of 23288.49 (ng*h/g)/(mg/kg), about 10 times higher than the second 
high organ spleen of 3350.07 (ng*h/g)/(mg/kg). The half-lives were comparable among 
all the organs, 2.74 ~ 4.77 h, except that in spleen, 1.92 h. (Table 29) 
CPT could be detectable more than 12 hours after CZ48 NS-L injection in all the major 
organs with the half-lives of 3.81 h ~ 8.24 h (Figure 35). In liver, CPT showed the highest 
Cmax/Dose of 31.03 (ng/g)/(mg/kg), followed by lung (20.95 (ng/g)/(mg/kg)), kidney 
(15.85 (ng/g)/(mg/kg)) and spleen (14.40 (ng/g)/(mg/kg)); and CPT also showed the 
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largest AUC0-/Dose of 189.48 (ng/g*h)/(mg/kg), followed by kidney (59.94 
(ng/g*h)/(mg/kg)), spleen (54.90 (ng/g*h)/(mg/kg)), and lung (39.55 (ng/g*h)/(mg/kg)).  
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Figure 35 Organ Distribution Profiles of CZ48 and CPT from Cosolvent in Mice 
(n=4) 
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Table 26 CZ48 and CPT Organ Distribution Parameters from Cosolvent in Mice after i.v. Administration 
(n=4) 
Parameters Unit 
Cosolvent 
Heart Liver Spleen Lung Kidney Brain Plasma
CZ48 
AUC0-/Dose (ng/g*h)/(mg/kg) 296.14 690.54 282.28 1038.38 604.57 59.59 156.05
Cmax/Dose (ng/g)/(mg/kg) 263.04 543.24 200.65 309.97 488.36 49.63 154.42
t1/2 h 0.76 0.84 0.93 2.00 0.81 0.62 0.70 
CPT 
AUC0-/Dose (ng/g*h)/(mg/kg) 18.75 99.03 34.34 34.18 57.25 8.25 2.89 
Cmax/Dose (ng/g)/(mg/kg) 11.18 50.99 21.46 29.26 21.78 7.28 3.53 
t1/2 h 0.99 1.17 0.81 0.77 1.48 0.68 0.40 
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Figure 36 Organ Distribution Profiles of CZ48 and CPT from NS-S in Mice (n=4) 
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Table 27 CZ48 and CPT Organ Distribution Parameters from NS-S in Mice after i.v. Administration (n=4) 
Parameters Unit 
NS-S 
Heart Liver Spleen Lung Kidney Brain Plasma
CZ48 
AUC0-/Dose (ng/g*h)/(mg/kg) 378.34 15324.07 5374.30 13686.92 332.13 34.61 178.06
Cmax/Dose (ng/g)/(mg/kg) 148.24 5521.13 3230.42 1689.83 194.71 9.99 49.48 
t1/2 h 8.29 1.96 1.64 38.21 3.20 4.45 8.00 
CPT 
AUC0-/Dose (ng/g*h)/(mg/kg) 32.93 181.38 48.51 55.18 57.35 8.91 6.89 
Cmax/Dose (ng/g)/(mg/kg) 11.55 34.22 16.15 18.71 17.38 3.91 2.51 
t1/2 h 7.13 6.31 2.99 7.28 4.16 4.02 12.51 
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Figure 37 Organ Distribution Profiles of CZ48 and CPT from NS-L in Mice (n=4) 
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Table 28 CZ48 and CPT Organ Distribution Parameters from NS-L in Mice after i.v. Administration (n=4) 
Parameters Unit 
NS-L 
Heart Liver Spleen Lung Kidney Brain Plasma
CZ48 
AUC0-/Dose (ng/g*h)/(mg/kg) 169.67 23288.49 3350.07 1612.12 355.41 34.14 146.85
Cmax/Dose (ng/g)/(mg/kg) 70.91 86253.18 2014.29 5036.33 386.09 9.41 69.79 
t1/2 h 4.77 2.74 1.92 3.07 3.17 4.16 5.58 
CPT 
AUC0-/Dose (ng/g*h)/(mg/kg) 23.16 189.48 54.90 39.55 59.94 8.24 3.81 
Cmax/Dose (ng/g)/(mg/kg) 10.73 31.03 14.40 20.95 15.85 4.15 1.55 
t1/2 h 6.49 5.99 4.58 3.81 8.24 4.04 5.81 
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4.3.3.4 Comparative Organ Distributions of CZ48 and CPT Following i.v. 
Administration of Cosolvent and Nanosuspensions (NS-S, and NS-L) 
of CZ48 in Mice 
The distribution patterns of CZ48 from nanosuspensions were different from that of the 
cosolvent. The exposures of CZ48 from both nanosuspensions were higher than that 
from the cosolvent in the RES rich system such as liver, spleen and lung (Table 29). On 
the contrary, the exposures of CZ48 in kidney, and brain from CZ48 of both 
nanosuspensions were lower than that from cosolvent. In addition, CZ48 from NS-S 
distributed more in spleen and lung (5374.30 vs. 3350.07 (ng*h/g)/(mg/kg), 13686.92 vs. 
1612.12 (ng*h/g)/(mg/kg), respectively), compare to NS-L from which CZ48 distributed 
more in liver (15123.00 vs. 22408.20 (ng*h/g)/(mg/kg)) (Table 30). The half-lives of CZ48 
from nanosuspensions were longer than those from cosolvent in all the organs (Table 
30). By comparing the biodistribution patterns of CPT among the three formulations, 
nanosuspensions had the highest exposure in liver, spleen, and lung, with long half-lives 
in all organs. The exposures of CPT in all the organs from NS-S were comparable to 
those from NS-L.  
4.3.3.5 Comparative Organ/Plasma Partition Coefficients of CZ48 and CPT 
Following i.v. Administration of Cosolvent and Nanosuspensions 
(NS-S, and NS-L) of CZ48 in Mice 
The organg/plasma partition coefficient (Kp) of CZ48 and CPT for the heart, liver, spleen, 
lung, kidney and brain were obtained experimentally from the Organ AUC/Plasma AUC 
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ratios toward the end of the study (Figure 38 ~ Figure 40). The Kp values of CZ48 in 
different organs were lower than those of CPT by cosolvent administration, which may 
be due to instabilities of CPT in plasma.  Similar results were found in nanosuspensions 
administration except in RES rich organs, liver, spleen, and lung. This due to the super 
uptake of nanoparticles by RES systems, and only free CZ48 can be biotranformed to 
CPT by CEs.  
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Table 29 Exposure (AUC0-t/Dose) of CZ48 and CPT from Cosolvent, NS-S and 
NS-L in Different Organs 
AUC0-/Dose [(ng/g)/(mg/g)] 
Organs
CZ48 CPT 
Cosolvent NS-S NS-L Cosolvent NS-S NS-L 
Heart 296.14 378.34 169.67 18.75 32.93 23.16 
Liver 690.54 15324.07 23288.49 99.03 181.38 189.48 
Spleen 282.28 5374.30 3350.07 34.34 48.51 54.90 
Lung 1038.38 13686.92 1612.12 34.18 55.18 39.55 
Kidney 604.57 332.13 355.41 57.25 57.35 59.94 
Brain 59.59 34.61 34.14 8.25 8.91 8.24 
Plasma 156.05 178.06 146.85 2.89 6.89 3.81 
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Table 30 Half-lives of CZ48 and CPT from Cosolvent, NS-S and NS-L in Different 
Organs 
t1/2 (h) 
Organs 
CZ48 CPT 
Cosolvent NS-S NS-L Cosolvent NS-S NS-L 
Heart 0.76 8.29 4.77 0.99 7.13 6.49 
Liver 0.84 1.96 2.74 1.17 6.31 5.99 
Spleen 0.93 1.64 1.92 0.81 2.99 4.58 
Lung 2.00 38.21 3.07 0.77 7.28 3.81 
Kidney 0.81 3.20 3.17 1.48 4.16 8.24 
Brain 0.62 4.45 4.16 0.68 4.02 4.04 
Plasma 0.70 8.00 5.58 0.40 12.51 5.81 
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Figure 38 Profiles of Partition Coefficient (Kp) of CZ48 and CPT from Cosolvent 
in Mice 
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Figure 39 Profiles of Partition Coefficient (Kp) of CZ48 and CPT from NS-S in 
Mice 
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Figure 40 Profiles of Partition Coefficient (Kp) of CZ48 and CPT from NS-L in 
Mice 
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4.4. NS-S Efficacy Study 
Based on the pharmacokinetic and organ distribution study in mice, NS-S was selected 
as the lead formulation to perform the efficacy study. Seven groups of tumor-bearing 
mice were used, receiving no treatment (NT), cosolvent placebo (CP), nanosuspension 
placebo (NP), CZ48 cosolvent (Co, 5 mg/kg), NS-S of low dose (NS-S-L, 5 mg/kg), NS-S 
of medium dose (NS-S-M, 25 mg/kg), and NS-S of high dose (NS-S-H, 50 mg/kg), 
respecting the same formulations used in the pharmacokinetic studies. Different doses 
between cosolvent and NS-S formulations were employed due to the toxicity of 
cosolvent formulation with 5 mg/kg as the maximum tolerable dose to the mice and the 
results of pharmacokinetic study in mice. The groups for NT, CP, and NP were used as 
control groups, and cosolvent as reference for comparison. The concentrations of CZ48 
(50 mg/kg) in the nanosuspensions were diluted to the required concentrations, and the 
tail vein injection dose was limited up to 0.2 ml or less. The control groups received 
equal volumes of placebo formulations. The drugs were dosed twice weekly for a total of 
8 doses. 
The tumor size was measured before the first dose and then twice weekly for 29 days. 
The size was recorded as a volume (Volume = Lengeh * Width * Hight). The growth of 
the tumor was expressed as V/V0, the ratio of the tumor volume on day of measurement 
to the initial volume on Day 1. The survival duration was expressed as the period 
between the day of sacrifice or death and the first day of dosing. The median survival 
was the time (expressed in days) when half the animals are expected to be alive. The 
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efficacy was definced as the suppression of tumor growth, the increase of survival 
duration and the median survial. The toxicity was expressed as the body weight loss. 
Mice were sacrificed if tumor volume was >7,000 mm3 or the body weight loss 
was >15%. 
Tumors were inoculated into 55 mice following the protocol described in Section 3.2.8.1. 
The tumor was allowed to grow for 10 days and when the tumor size was between 100 ~ 
300 mm3. The mice were randomized using Microsoft FoxPro 7.0 based on the tumor 
size and the body weight, into groups and given the first dose. 
4.4.1. Tumor Growth Rate 
The comparative tumor growth, V/V0 ratio, versus the time from the first day of dosing to 
day 11 and day 29 of treatment period in days was shown in Figure 41 for different 
groups. In day 11, the mice in each control group (NT, CP, NP) and reference group (Co) 
started to be sacrificed due to the tumor size was larger than 7000 mm3, the comparison 
to day 11 was more presice compared to the comparison to day 29 because of the 
observation number due to the animal death.  
The growth rate /day for each group to day 11 treatment was calculated according to the 
exponential tumor growth model, as summarized in Table 31, and ANOVA followed by 
Tukey’s post-hoc statistical analysis was conducted (Table 32). The growth rates were 
0.157 ± 0.048 day-1 ~ 0.192 ± 0.049 day-1 for the three control groups, 0.181 ± 0.064 
day-1 for cosolvent, 0.130 ± 0.030 day-1 for NS-S-L, 0.084 ± 0.030 day-1 for NS-S-M, and 
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0.010 ± 0.003 day-1 for NS-S-H, respectively. The tumor growth rate of NS-S-L group did 
not show significant difference from Co group; however, both NS-S-M and NS-S-H 
groups had statistically slower tumor growth rate as compared to that of all the control 
groups. Moreover, the tumor growth rate of NS-S-H group was statistically slower than 
that of NS-S-M group  
4.4.2. Average Body Weight 
Body weight loss was considered toxicity. The average body weights of groups versus 
the day post first dose were monitored (Figure 42). No statistical difference was 
observed in the body weights when among different groups except NS-S-H group.  
4.4.3. Survival Rate 
The survival rates of mice in three control groups, cosolvent reference group and three 
nanosuspension treatment groups were shown in Figure 43. The survival rate was 
expressed as percent of mice surviving from original number at time 0. The median 
survival was estimated as 8 ~ 15 days for three control groups, 18 days for cosolvent 
reference group, and 22 days for NS-S-L, more than 29 days for NS-S-M, and 15 days 
for NS-S-H (Table 33). CZ48 nanosuspensions of low and medium doses prolonged the 
animal survival. However, the high dose group did not show merits to the animal survival 
due to the toxicity. 
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Figure 41 Tumor Growth versus Time from the First Day of Dosing to Day 11 and 
Day 29 of Treatment Period. n=7 in Blank, CP, NP Groups, n=10 in Co 
(5 mg/kg), NS-S-L (5 mg/kg), NS-S-M (25 mg/kg) and NS-S-H (50 mg/kg) 
groups.  
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Table 31 Tumor Growth Rate from the First Day of Dosing to Day 11 of 
Treatment 
Groups Day 11 
NT (n=7) 0.192  0.049
CP (n=7) 0.157  0.048
NP (n=7) 0.191  0.052
Co (n=10, 5 mg/kg) 0.181  0.064
NS-S-L (n=10, 5 mg/kg) 0.130  0.030
NS-S-M (n=10, 25 mg/kg) 0.084  0.030
NS-S-H (n=10, 50 mg/kg) 0.010  0.003
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Table 32 ANOVA with Tukey’s Post-hoc Analysis Testing for Tumor Growth 
Rate from the First Day of Dosing to Day 11 of Treatment  
One-way analysis of variance 
P value < 0.0001 
P value summary *** 
Are means significantly different? (P < 0.05) Yes 
Number of groups 7 
F 14.20 
R squared 0.6543 
 
 170 
 
Table 32   ANOVA with Tukey’s Post-hoc Analysis Testing for Tumor Growth Rate  
      from the First Day of Dosing to Day 11 of Treatment (Cont’d) 
 
Tukey's Multiple Comparison Test Significant? P < 0.05? Summary 
NT vs CP No ns 
NT vs NP No ns 
NT vs Co No ns 
NT vs NS-S-L No ns 
NT vs NS-S-M Yes ** 
NT vs NS-S-H Yes *** 
CP vs NP No ns 
CP vs Co No ns 
CP vs NS-S-L No ns 
CP vs NS-S-M No ns 
CP vs NS-S-H Yes *** 
NP vs Co No ns 
NP vs NS-S-L No ns 
NP vs NS-S-M Yes ** 
NP vs NS-S-H Yes *** 
Co vs NS-S-L No ns 
Co vs NS-S-M Yes ** 
Co vs NS-S-H Yes *** 
NS-S-L vs NS-S-M No ns 
NS-S-L vs NS-S-H Yes *** 
NS-S-M vs NS-S-H Yes * 
Note: “ns”, no significant difference 
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Figure 42 Average Body Weight of Each Group versus the Day after the First 
Dose. No Statistical Difference was Observed in the Body Weights 
among Different Groups (Co, 5 mg/kg, NS-S-L, 5 mg/kg, NS-S-M, 25 
mg/kg, and NS-S-H, 50 mg/kg) 
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Table 33 Median Survival (Days) 
Median Survival (Days) 
NT (n=7) 8 
CP (n=7) 11 
NP (n=7) 15 
Co (n=10, 5 mg/kg) 18 
NS-S-L (n=10, 5 mg/kg) 22 
NS-S-M (n=10, 25 mg/kg) >29 
NS-S-H (n=10, 50 mg/kg) 15 
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The Kaplan-Meier plot was used for survival analysis comparison. The p-values for the 
10-way comparison are summarized in Table 34. NS-S-M group was statistically 
different from all the control groups, cosolvent group and other treatment groups with a 
p-value of 0.0002 ~ 0.0029. The comparison survival plots among different groups were 
conducted (Figure 44 ~ Figure 46). There was no significant difference among these 
three control groups without CZ48 treatment (NT, CP and NP) with a p value of 0.3356 
(Figure 44). Moreover, NS-S-M i.v. administration showed an improved survival 
compared to the no treatment control group and cosolvent reference group (p=0.0023, 
Figure 45). The high dose group showed significantly stronger tumor suppression 
compare to low and medium dose groups; however, the low survival rate indicated a 
high toxicity (p = 0.0230, Figure 46).  
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Figure 43 Percent Survival in Each Group over Time in Days. The Survival was 
Expressed as % Surviving from Original Number at Time 0. (Co, 5 
mg/kg, NS-S-L, 5 mg/kg, NS-S-M, 25 mg/kg, and NS-S-H, 50 mg/kg) 
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Table 34 Summary of Kaplan-Meier Survival Analysis Significance Testing 
among Different Groups 
Survival Comparison 
 Co NS-S-L NS-S-M NS-S-H 
CP 0.0453 - - - 
NP - 0.0219 0.0002* 0.2046 
Co - 0.2309 0.0011* 0.4765 
NS-S-L - - 0.0085 0.9646 
NS-S-M - - - 0.0167 
* Indicated statistically significant differences in survival among the groups at p < 0.005 
for a 10-way comparison in Kaplan-Meier Analysis.  
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Figure 44 Kaplan-Meier Survival Plot among Control Groups (NT, CP and NP) 
with p value of 0.3356 
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Figure 45 Kaplan-Meier Survival Plots among NT, Co and NS-S-M Groups with p 
value of 0.0023 
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Figure 46 Kaplan-Meier Survival Plots among Nanosuspension Treatment 
Groups (NS-S-L, NS-S-M and NS-S-H) with p value of 0.023 
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Chapter 5 Discussion 
CPT is naturally occurring anti-neoplastic agent that inhibits the nuclear enzyme Topo-, 
which is overexpressed in certain tumor types including those of cervix and colon 
(McLeod HL et al., 1994; Giovanella BC et al., 1989). The lactone moiety of CPT is 
unstable in vivo, but essential for the anti-tumor efficacy. Cytotoxicity of Topo- inhibitors 
is S-phase cell-cycle specific and in vitro and in vivo studies have suggested that 
prolonged exposure to low concentrations is more relevant for efficacy than a short-term 
exposure to high concentrations (Gerrits CJ et al., 1997). Poor aqueous solubility is a 
major chemical characteristics of CPT and the development of more water-soluble 
analogues is one of the two major approaches in CPT research, along with the 
development of more lactone-stable derivatives. 
Currently, numerous CPT analogues are at different stages of drug development. At 
present, two water-soluble CPT analogues have been approved by FDA for clinical use 
in the U.S.: Topotecan (Hycamptin), indicated as a second-line therapy for advanced 
ovarian and small cell lung cancers, and irinotecan (Camptosar), indicated for the 
treatment of advanced colorectal cancer. However, the response rates of clinical 
anticancer activity of these two products were modest, 12-50% depending on the type of 
cancer being treated (Takimoto CH et al., 1998). This is modest efficacy due to the fact 
that at physiological pH, the equilibrium favors the inactive carboxylate form over the 
active lactone species. 
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CZ48, a novel propionate ester of CPT, demonstrated superior lactone stability over 
CPT both in vitro and in vivo. CZ48 exerts its anti-neoplastic activity after hydrolysis to 
CPT by the action of carboxyestrase (Liehr JG et al., 2000). However, the solubility of 
CZ48 is extremely low, which is only 57.22 ~ 63.20 ng/ml at physiology pH (Pfuma E, 
2008). CZ48 is the C20-propinate derivative of CPT, an alkaloidal compound. This group 
of compounds has a weakly basic character. Therefore, it was not surprising to display a 
2-fold increase in solubility at pH 1. Although the amide nitrogen in ring C of the 
molecule possesses very low basicity, the non-bonding electron pair on the quinoline 
nitrogen, ring B, is localized and available for protonation at this low pH (Chen HJ et al., 
1971). Irrespective of that, CZ48 solubility of 116.02 ng/ml at pH=1 is still considered 
very low. In addition, any pharmaceutical preparation at this extreme pH is impractical. 
The low aqueous solubility of CZ48 clearly demonstrates the need for formulation efforts 
to significantly improve solubility, especially if an intravenous drug delivery is to be 
pursued to reach the therapeutic concentrations. Erratic bioavailability also was found 
when orally dosing it unformulated.  
Poorly-water soluble drugs represent a formulation challenge and it is pharmaceutical 
formulator’s responsibility to find the optimum approach to overcome this limitation. 
Facing those challenges, we found nanoformulation technique is promising for this class 
of drug candidates that have low water solubility and require sustained exposure to 
achieve the maximum therapeutic effects. Therefore, we proposed that if we succeed in 
continuously delivering CZ48 at a low and sustained rate by a nanoformulation, we could 
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potentially provide sustained and prolonged concentration of CPT near or at the site of 
action, thus accomplishing an optimal therapeutic outcome. 
The success of CZ48 nanosuspension preparation could increase the dissolution rate 
and the saturation equilibrium solubility by reducing the particle size of CZ48 to a nano-
sized range. Then CZ48 nanosuspension could be administered by a variety of routes, 
such as oral, intravenous, ocular and pulmonary and so on. We aim to administer CZ48 
nanosuspension by intravenous to avoid first-pass effect, providing the most rapid effect, 
and/or achieving a passive target effect. Moreover, the injection volume of 
nanosuspension will not exceed the limitation of the volume of i.v. administration owing 
to the its high drug load, and the therapeutic responses as well as associated toxicity 
can be more predictable (Wong J, 2008).  
This project involved the development, optimization, and characterization of 
nanosuspension formulations of CZ48 for intravenous delivery. The formulation work 
was preceded by a thorough screening study of stabilizers and preparation time. CCD 
was also carried out to optimize the properties of CZ48 nanosuspensions.  
From the obtained formulations, two formulations with different particle sizes were 
investigated for the pre-clinical pharmacokinetics and organ distribution patterns in two 
rodent species, rats and mice, upon i.v. administration, and were compared to those 
from CZ48 cosolvent administrations in an attempt to demonstrate the versatility of 
application of the developed formulation.  Then based on the information obtained from 
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the pharmacokinetic and biodistribution studies, a lead formulation was selected and 
was subject to test the antitumor activity in a tumor bearing mouse model.  
We were interested in lung cancer because it is the leading cause of cancer mortality in 
the United States, Europe, and many other industrialized countries. NSCLC differs from 
SCLC in that surgery can frequently be curative, albeit in a small subpopulation of 
patients (Devore RF and Johnson DH, 1996; Bonomi P, 1996). NSCLC displays the 
same characteristics as many solid tumors for which single-agent chemotherapy 
provides only a small response rate, and even combination chemotherapy produces only 
marginal survival improvements. This discouraging picture underscores the need for new 
therapeutic approaches for NSCLC. Besides the H460 cell line is very invasive. The 
average volume doubling time in the first passage in nude mice is around 7 days 
(Mattern J et al., 1985).  
This project was unique in many perspectives: 
First, it involved the development of a novel formulation, nanosuspension, for a novel 
CPT derivative, CZ48, for which superior lactone ring stability has been confirmed both 
in vitro and in vivo.  
Second, a screening study was performed with 5 different stabilizers, used 3 
concentrations, and their combinations.  Moreover, the influences of the multiple 
preparation factors were evaluated and optimized with a surface response design using 
only a truncated set of empirical experiments and the statistical modeling of this 
empirical data, which were appropriate by meeting the assumptions.  
 183 
 
Third, it proved the concept that achieving and sustaining therapeutic levels of the active 
moiety, CPT, in plasma and organ tissues were feasible upon i.v. administration of CZ48 
nanosuspension formulation compared to CZ48 cosolvent.  
Fourth, it demonstrated the significant antitumor activity with a higher tolerable dose by 
i.v. administration of CZ48 nanosuspension in xenograft tumor bearing mouse model.   
5.1. CZ48 Nanosuspensions Preparation 
Mainly there are two methods for the preparation of nanosuspensions: Bottom-up 
process and Top-down process (Verma S et al., 2009). In the bottom-up approach the 
drug is dissolved in an organic solvent and is then precipitated on addition of an anti-
solvent in the presence of stabilizer. The limitation of this precipitation method is that the 
drug needs to be soluble in at least one solvent and this solvent needs to be miscible 
with nonsolvent. Moreover, this technique is not applicable to drugs that are 
simultaneously poorly soluble in aqueous and nonaqueous media (R.H Muller, handbook, 
2000). The top-down method is the disintegration method and is preferred to the 
precipitation method. It includes media milling (nanocrystal), high pressure 
homogenization in water (dissocubes), high pressure homogenization (nanoedege) 
(Keck CM and Müller RH, 2006). Media milling method can be applied to the drugs that 
are poorly soluble in both aqueous and organic media. It is also easy to scale-up and 
has little batch-to-batch variation (Patravale VB et al., 2004). The final nano-sized 
product shows narrow size distribution. It’s also flexibility in handling the drug quantity, 
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ranging from 1 to 400 mg/ml, enabling formulations of very dilute and highly 
concentrated. 
Based on the above advantages, the media milling technique is used in nanosuspension 
preparation where the solid drug particles are sheared between the sliding surfaces of 
the moving glass beads. This shear movement imparts energy into the system leading to 
the reduction of the particle size. Due to the energy introduced into the system to reduce 
the particle size, the system becomes thermodynamically unstable due to the formation 
of fresh surfaces. It tends to reduce the high energy by re-agglomeration into larger 
particles to minimize the newly created surfaces. To overcome the agglomeration 
tendency, surface active compounds (surfactant) could be used to stabilize the 
suspension particles. There are only a limited numbers of nonionic and anionic 
surfactants that have been approved as excipients for parenteral use, including 
phospholipids, T-80, and poloxamers. There are many safety concerns about the use of 
anionic surfactants (Bummer P, 2000). With this consideration, 5 nonionic surfactants 
and there combinations with T-80 were investigated. T-80 and F-108 were selected from 
several stabilizer candidates as steric stabilizers to overcome the attractive interactions 
between the sheared particles. The surfactant F-108 has also been used in the 
formulation of i.v. injectable itraconazole and the clinical trial of its suspension has also 
been conducted (Mouton JW et al., 2006). The presence of the stabilizers keeps the 
particles apart and prevents the re-agglomeration. 
To further reduce the particle size, the shear forces are increased by minimizing the 
distances that separate the sliding beads, using a mixture of glass beads with various 
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sizes to incorporate the smaller beads in-between the larger ones (Kesisoglou F et al., 
2007). The single-sized glass beads produce particles with a larger polydispersity index 
(bi-modal size distributions), but a mixture of multi-sized glass beads produces a narrow 
polydispersity index (mono-modal particle size distribution). Similar results are reported 
by Yang (Yang JZ et al., 2008).  
5.2. Central Composite Design (CCD) 
Preparation of nanosuspensions is a complex procedure as it involves several 
processing variables and design components. These variables and system components 
also demonstrate significant interactions among themselves that affect the quality of final 
products. For a successful formulation development, it is extremely important to identify 
these critical factors ad their interactions that have potential impacts on the quality 
attributes and performance characteristics of the product.   
The use of experimental techniques, such as CCD, is the most rational and systematic 
way for simultaneous identification, estimation, and analysis of influence of critical 
factors on the quality of final formulation (Zhang J et al., 2008; Kollipara S et al., 2010). 
Without the use of CCD, only a few variables can be studied at a limited number of 
levels because of the fact that many experiments are required to draw a significant 
conclusion. When cost and time of each experiment is very high, the use of CCD can 
offer possibility of analyzing a large number of variables with a limited experiment runs 
(Molpeceres J et al., 2009; Lewis GA et al., 1999; Aktas E et al., 2012; Hao J et al., 
2012).  
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The tendency of smaller particles in a suspension to dissolve and re-grow on bigger 
particles presents a mode of instability, termed “Ostwald ripening”. It has been reported 
that too much dispersant used in the stabilization of a suspension could actually promote 
Ostwald ripening. The proposed weight ratio of drug to stabilizer was advocated to be in 
the range of 20:1 to 2:1 (Merisko-Liversidge E et al., 2003). This theory is consistent with 
our CCD results. Out of the three factors studied, CZ48 concentration and F-108/CZ48 
ratio had considerable impacts on the mean particle size with a p value less than 0.05. 
Particle size changes steeply by varying CZ48 concentration, but changes in a relatively 
gradual fashion with the F-108/CZ48 ratios. Schubert and Muller-Goymann reported that 
an increase of stabilizer concentration led to a concentration dependent increase in 
particle size once the stabilizer concentration exceeded a critical concentration, which 
seems to be consistent with our study (Schubert MA and Müller-Goymann CC, 2003).  
The zeta potential was not significantly affected by the experimental conditions 
employed in this study. A preferred zeta potential should provide a sufficient electric 
repulsion to prevent the nanoparticles from aggregation and agglomeration (Gao Y et al., 
2010). In order to obtain a nanosuspension exhibiting a good stability, a minimum zeta 
potential of ± 20 mV is desirable (Müller RH and Jacobs C, 2002). Most of the 
nanosuspensions produced by FDA proved surfactants have a negative charge 
(Möschwitzer JP, 2012). For those positively charged surfactant, it is unsuitable for use 
in humans. Moreover, the negatively charged particles have a similar charge of the 
cellular membrane, and the particles will be strongly adsorbed onto the cellular 
membrane.  
 187 
 
The particle size is the most basic property of a nanosuspension system. In addition, the 
other characterizations (saturation solubility, dissolution rate, physical stability, or even 
biological performances) of a nanosuspension system are also governed by the particle 
size (Gao L et al., 2008). According to Noyes-Whitney, the decreased particle size can 
increase the effective particle surface area and consequently, the dissolution rate 
(Patravale et al., 2004). It is well known that, a small particle size with a narrow size 
distribution can alleviate the agglomeration to ensure a stable and homogeneous system. 
As reported in the study of Wang et al. (Wang et al, 2010), nanosuspension A (642 ± 15 
nm) and nanosuspension B (127 ± 2 nm) showed different bioavailability improvements 
with absolute bioavailability of 39.6% and 50.9%, respectively, compared to the unmilled 
suspension (17.4%) after oral administration. Previous research in our lab has proven 
that only the nanosuspension of size above 500 nm yields a significant difference in 
pharmacokinetic behavior in vivo from that of 200 nm (Qi YL, 2008). Therefore, the 
nanosuspensions with particle sizes of 200 nm and 600 nm were selected as the model 
formulations for further investigation. The zeta potential values of our final formulations 
are -26.5 ± 0.9 and -27.9 ± 0.8 mV for NS-S and NS-L, respectively, which would be 
sufficient to prevent the nanoparticles from aggregation and agglomeration. 
5.3. Stability of CZ48 in Nanosuspension Formulations (NS-S 
and NS-L) 
Physical stability evaluations of CZ48 in the two nanosuspensions revealed that the 
formulations were stable over 6 months. CZ48 chemical stability under different 
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conditions has already been established by Dr. Yousif Rojeab (Yousif R, 2007). 
Chemical stability of CZ48 solution at pH 7.4 as well as at pH 5.0 was evaluated under 
accelerated stability conditions to extrapolate the stability to room temperature. 
Particularly, from a drug development perspective, a shelf life of less than two years is 
usually required since batch approval, release and distribution; it can easily take up to 
six months. It also displayed consistency in CZ48 load 50 mg CZ48 per ml, from batch-
to-batch, when prepared under the uniform conditions.  
5.4. HPLC Assay 
It is of crucial importance to be able to quantify the concentrations of CZ48 and the 
active moiety, CPT, simultaneously in the HPLC assay method used, since both species 
coexist in analytical samples generated from both in vitro and in vivo studies.  
A previously developed isocratic HPLC method was used for the simultaneous 
quantifications of CZ48 and CPT concentrations in aqueous samples over the 
concentration range of 10 ~ 150 and 5 ~ 100 ng/ml for CZ48 and CPT, respectively (Li 
XH, 2004). With this assay, base-line peak resolution was achieved for all three species, 
CZ48, CPT and CZ44 (IS).  
Another simple and sensitive gradient high-performance liquid chromatography (HPLC) 
assay for the analysis of CZ48, CPT in mouse plasma was developed and validated by 
Xin Liu (Liu X et al., 2008). The mean recoveries at three concentrations of 10, 100 and 
900 ng/ml were 81.41 ± 0.035%, 86.00 ± 0.053% and 82.21 ± 0.020% respectively, for 
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CZ48 and 76.01 ± 0.028%, 77.04 ± 0.042% and 85.93 ± 0.023% respectively, for CPT. 
The calibration curves were linear (r2=0.9999) over CZ48 and CPT concentrations 
ranging from 10 ~ 1000 ng/ml and 5 ~ 1000 ng/ml (n=6), respectively. The method had 
an accuracy of >95% and intra- and inter-day precisions of <1.2% and <2.2% 
respectively, for CZ48 and CPT, at three different concentrations (10, 100 and 900 
ng/ml). The lower limits of quantification (LLOQ) using 0.1 ml mouse plasma were 10 
ng/ml for CZ48 and 5 ng/ml for CPT.  
Solid phase extraction (SPE) method was applied to prepare plasma samples in the 
originally developed method; however, organic solvent precipitation with diethyl ether 
was used to prepare mouse plasma in Liu’s article. For our case, the HPLC assay 
method developed and validated by Liu was modified using organic solvent precipitation 
with acetonitrile to prepare plasma and organ samples from the pharmacokinetic studies 
and organ distribution studies in rats and mice. Organic precipitation yielded high 
recovery for CZ48 and CPT, about 96%. The lower limits of quantification (LLOQ) were 
0.78 ng/ml for CZ48 and 0.55 ng/ml for CPT. A significant enhancement from the 
published method (Liu X et al., 2008). 
In addition, it was cost-effective since SPE cartridges are for single-use. Organic 
precipitation with ice-cold acetonitrile added at a ratio of 5:1 to plasma or homogenized 
organ samples. The samples of clear supernatant after centrifugation were evaporated 
under air. The same volume of mobile phase was used to reconstitute the sample, which 
will not dilute the drug concentrations. It is critical especially for the last few time points 
when the concentrations of active metabolite, CPT, were very low. In conclusion, the 
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HPLC method was highly sensitive, reproducible and efficient in quantifying CZ48 and 
CPT concentrations simultaneously from in vivo studies. 
5.5. In-vitro Release of CZ48 from Cosolvent and Two 
Nanosuspensions (NS-S and NS-L) 
The in vitro release characteristics of CZ48 from the selected nanosuspension 
formulations of different particle sizes were evaluated in PBS and human plasma, as an 
essential characterization criterion and for selection optimal formulationfor the potential 
use for i.v. drug delivery. PBS can help to maintain a constant pH which is mimicking the 
human physiological environment. The osmolality and ion concentrations of the solution 
usually match those of the human body (isotonic).  
The results showed that CZ48 nanosuspensions exhibited distinct release profiles from 
that of CZ48 cosolvent formulation. From the release study in aqueous PBS media, the 
release rate of CZ48 from cosolvent was very rapid, and a complete release was 
achieved within 2 hours. In contract, the release rates of CZ48 from nanosuspensions 
were significantly slower than that of CZ48 cosolvent, and reach a complete release by 6 
hours. The CZ48 nanosuspension with a larger particle size (600 nm) exhibited 
significantly slower release rate compare to that of CZ48 nanosuspension with a smaller 
particle size (200 nm).  
Similarly, in vitro release of CZ48 from nanosuspensions of various sizes in plasma was 
much slower than that of CZ48 cosolvent, as CZ48 was completed release from 
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cosolvent in 48 hours, while only 40% were released in 48 hours from nanosuspensions 
of the two sizes.  
The immediate release profile of cosolvent and slower release profiles of CZ48 
nanosuspensions, including NS-S and NS-L, could be explained by their different 
physical nature. In cosolvent formulation, CZ48 molecules are completely dissolved in 
the cosolvent mixture. The dissolved CZ48 molecules are readily to be transferred from 
the dialysis bag to the outside media. In contrast, nanosuspensions contain solid drug 
particles of nanomicron sizes, and the drug molecules need to be dissolved into the 
diffusion layer first and then into the bulk media before being released from the dialysis 
bag (Hsu WC and Lin SP, 1991). The slow dissolving process contributes to the 
slower/sustained release profiles of CZ48 from the nanosuspensions. The initial release 
rate of small-sized CZ48 nanosuspension (NS-S) was significantly higher than that of 
large-sized NS-L. The mean values of initial rates of nanosuspensions of various sizes 
increased as the particle size decreased, which is consistent with the previous work in 
our lab by Qi (Qi YL, 2008). According to Noyes-Whitney equation, the dissolution rate 
will increase due to the increase of surface area when particle size reduces (Aulton ME, 
2002). 
In vitro release study in plasma mimicked the release kinetics of CZ48 cosolvent and 
nanosuspensions in blood circulation after an i.v. injection. The distinct release profiles 
of CZ48 nanosuspensions from that of CZ48 cosolvent formulation in plasma suggests 
that these two types of formulations release CZ48 differently in vivo. However, there is 
no significantly different between the two nanosuspensions of different particle sizes that 
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might be due to the high protein binding of CZ48; 82.48  2.52 %. The drug molecules 
also need to be dissolved into the diffusion layer first and then into the bulk media before 
being released from the dialysis bag. Then the drug molecules bind to the protein and 
hard to release from the dialysis bag. Therefore, the particle size of nanosuspensions 
did not apparently affect the in vitro release of CZ48 in plasma.    
5.6. Pharmacokinetics and Organ Distribution of CZ48 NSs 
Pharmacokinetic and organ distribution studies were conducted in SD rats and Swiss 
nude mice to comparatively evaluate the plasma pharmacokinetics and biodistribution of 
CZ48 cosolvent and nanosuspensions of two particle sizes (NS-S and NS-L). For 
nanosuspension system, studies have demonstrated that the particle size could also 
affect the in vivo performance, such as bioavailability and duration of drug effects 
(Chingunpitak J et al., 2008; Kassem MA et al., 2007; Wong J et al., 2008). Therefore, it 
is of great importance of this study to investigate the impact of physical nature of 
parenteral formulation on CZ48 disposition in rodent animals by comparatively 
establishing the plasma and organ profiles for different types of CZ48 parenteral 
formulations. The effects of the particle size of CZ48 nanosuspensions on the 
pharmacokinetics and biodistribution patterns were also established. Consequently, the 
different disposition of CZ48 yielded a significantly different pharmacokinetic and 
biodistribution behavior of its active metabolite CPT. 
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5.6.1. Plasma Pharmacokinetics of CZ48 Cosolvent and 
Nanosuspensions (NS-S, and NS-L) in Rats 
From plasma pharmacokinetic results, CZ48 nanosuspensions exhibited distinct 
pharmacokinetic characteristics from that of CZ48 cosolvent.  
Longer β half-life for CZ48 nanosuspensions than that from cosolvent was partially 
attributed to the sustained drug release from nanosuspensions. Another possible reason 
for prolonged β half-life could be due to the RES uptake of nanoparticles in 
nanosuspensions, and then the drug was released from phagocytic cells to blood 
circulation due to the drug concentration gradient, which resulted in a longer blood level 
compared to that from cosolvent (Liu Y et al., 2012). CZ48 nanosuspension also yielded 
much larger Vss than cosolvent, which reflected significant dispositions of CZ48 in the 
peripheral compartments.  
In the recent study of oridonin nanosuspensions in rabbits, the nanosuspensions of 897 
nm was observed to exhibited distinct plasma pharmacokinetic properties from oridonin 
solution, such as a prolonged β half-life and large volume of distribution (Gao L et al., 
2008). However, the oridonin nanosuspension of 103 nm exhibited a rapid in vitro 
dissolution as oridonin solution. As a result, the nanosuspension of 103 nm showed a 
similar plasma pharmacokinetics to that of the solution. In our studies, the in vitro 
dissolution profile of NS-S was similar to NS-L in plasma, while distinct from that of 
cosolvent. In this way, NS-S shared the similar plasma pharmacokinetic properties, such 
as low C0, prolonged β half-life and large volume of distribution, as those of NS-L, while 
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those plasma pharmacokinetic properties were significantly different from that of 
cosolvent. The water solubility of oridonin is 0.7 g/L, significantly higher than that of 
CZ48 which is less than 63.2 ~ 57.2 ng/ml at pH 3 ~ 7. The solubility difference may 
explain the differences of in vitro dissolution and in vivo pharmacokinetics of 
nanosuspensions of 100 nm to 200 nm (Xu W et al., 2007). Other possible influencing 
factors could be the physiochemical differences in melting point and lipophilicity between 
oridonin and CZ48.  
The particle size of nanosuspensions also has significant impacts on the plasma 
pharmacokinetics of CZ48 from nanosuspensions, which can be attributed to two 
reasons: size-dependent dissolution rate and RES uptake (Gao L et al., 2008; 
Manjunath K and Venkateswarlu V, 2005). The smaller-sized of CZ48 nanosuspenison 
(NS-S) yielded a significantly higher C0 than the larger-sized nanosuspension (NS-L). 
The V1 was smaller for NS-L than that of NS-S, indicating a greater drug uptake into the 
peripheral compartment from NS-L than NS-S. The nanoparticles with larger size are 
taken up more efficiently than those with smaller particle size in in vitro studies with 
macrophage cells (Allen TM and Everest JM, 1983; Chono S et al., 2006). Since the 
particle size of nanosuspension affect plasma pharmacokinetics, one can carefully select 
the particle size based on the therapeutic need. 
The pharmacokinetic and distribution behaviors depend on the chemical properties, 
CZ48 disposition, as well as the transformation rate and capacity of CZ48 to CPT in 
each organ. Only free dissolved CZ48 can be converted to CPT. In this way, the CPT 
from NS-S also showed a significantly longer elimination half-life compared to those from 
 195 
 
NS-L and cosolvent. There were a comparable Vss among those three groups that could 
be interpreted as only the chemical properties could affect the CPT disposition at steady 
state.  
5.6.2. Plasma Pharmacokinetics of CZ48 Cosolvent and 
Nanosuspensions (NS-S, and NS-L) in Mice 
Athymic nude mice are animal models of choice for pharmacokinetics and 
pharmacodynamics studies of anticancer agents, because they can easily grow human 
tumor by injecting human tumor cells. Moreover, the Swiss nude mice will be the tumor 
model to test the efficacy of the lead nanosuspension. Therefore, the mouse model was 
also selected for the preclinical pharmacokinetic and biodistribution studies of CZ48 from 
cosolvent, and nanosuspensions in our project.  
The blood volume of mice is 6-8% of the body weight and no more than 10-15% of total 
blood volume should be collected at one time (Hoff J, 2000). Due to this limitation, there 
were no more than three plasma samples could be obtained from each mouse for the 
plasma pharmacokinetic studies of CZ48 from cosolvent and nanosuspensions in mice. 
Therefore, combined with the organ distribution study, we withdraw only one additional 
plasma sample for each mouse before organ collection. A naïve averaged plasma 
approach was used to construct plasma-time profiles for CZ48 from cosolvent and 
nanosuspensions in mice. In naïve average plasma approach, the averaged plasma 
concentration at each time point was calculated. Based on the mean plasma 
concentration-time profile, the mean pharmacokinetic parameters which reflected 
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population pharmacokinetic properties were derived by WinNonlin (KuKanich B et al., 
2007). Without pharmacokinetic parameters from each individual mouse, statistical 
comparison such as ANOVA test among those formulations could not be performed in 
our studies. Instead, the possible trend of changes of pharmacokinetic parameters 
between formulations was evaluated by comparing the magnitude of the values. 
Similar as in rats, CZ48 nanosuspensions of two different particle sizes (NS-S and NS-L) 
also exhibited distinct plasma and biodistribution patterns from that of cosolvent. 
Significantly lower C0 of CZ48 from both nanosuspensions than that from the cosolvent 
formulation could be due to the slower dissolution rates of CZ48 from the 
nanosuspensions than from cosolvent. The in vitro drug release studies demonstrated 
that CZ48 from cosolvent was rapidly and completely released, while CZ48 from 
nanosuspensions was released much slower in the plasma. Two-compartmental model 
was used to characterize the CZ48 plasma profiles from nanosuspensions, while one-
compartmental model was used for the CZ48 profile from the cosolvent. It could be due 
to the drug accumulation in the peripheral compartment from CZ48 nanosuspensions. 
Longer elimination half-lives and larger Vss were observed in nanosuspensions than 
those of CZ48 from cosolvent. The microconstants K21 of both nanosuspensions were 
slightly slower than K12. No significant differences were observed between NS-S and 
NS-L.  
The decreased C0 and prolonged half-lives of nanosuspensions, as compared with 
cosolvent could be significant in clinical application of nanosuspensions. For example, 
the decreased C0 could be beneficial in reducing side effects of the drug caused by the 
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excessively high C0 (Kim WY et al., 2007). CZ48 nanosuspension with a prolonged half-
life needs less frequent dosing to provide a sustained therapeutic plasma level of CPT, 
which is more convenient to patients and favors a better patient compliance.  
More importantly, similar as the result in rats, the CPT from NS-S also showed a 
significantly longer elimination half-life compared to those from NS-L and cosolvent. 
There were a comparable Vss of CPT among those three groups. 
5.6.3. Organ Distribution of CZ48 Cosolvent and Nanosuspensions 
(NS-S, and NS-L) in Rats 
Consistently distinct plasma pharmacokinetic properties of CZ48 nanosuspensions from 
those of cosolvent in rats and mice, such as prolonged β half-lives and large volume 
distribution for CZ48 nanosuspensions, drive our investigation to establish the 
biodistribution patterns of CZ48 from nanosuspension formulations, in contrast to that of 
cosolvent. 
The organ distribution patterns of CZ48 from nanosuspensions were distinct from that of 
CZ48 cosolvent. CZ48 distributions among organs from cosolvent were relatively even 
among organs, due to the rapid dissolution and highly hydrophobic properties of CZ48, 
except a high accumulation in lung that may be due to the drug precipitation with 
subsequent retention in lung, which was consistent with the finding of bifendate 
nanosuspension study in rabbits (Liu Y et al., 2012). Further research was needed in the 
future. The liver and spleen were observed with the highest exposure of CZ48 from 
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nanosuspensions, which could be due to the RES uptake. Liver and spleen are known 
as two major sites containing the RES as the one of the body defense system to clear 
foreign particles (Brannon-Peppas L & Blanchette JO, 2004). The particles circulating in 
the blood stream, will be immediately uptaken by the RES (Burgess DJ, 2005; Gao L, 
2008), as reported with high drug dispositions in liver and spleen from oridonin 
nanosuspensions of 897 nm (Gao L et al., 2008). The pattern of high drug distributions 
in liver and spleen from nanosuspensions is very similar to that of liposome and other 
nanoparticle formulations (Allen TM and Everest JM, 1984; Brannon-Peppas L & 
Blanchette JO, 2004; Freise J et al., 1981; Peters K et al., 2000). Following the uptake, 
the RES acts as a depot and drug can be released slowly back to the systemic 
circulation, which may contribute to the sustained plasma drug level achieved from 
nanosuspensions (Burgess DJ, 2005).  
CZ48 exerts the antitumor activity by CEs mediated hydrolysis to the active metabolite 
CPT in vivo (Liehr JG et al., 2000). In vitro study of CZ48 metabolism has showed that 
among blood and CE-containing tissues such as liver, spleen, lung and kidney, the liver 
has the highest metabolic capacity to convert CZ48 to CPT (Satoh T and Hosokawa M, 
1998) instead of in blood, consistent with the fact that the highest CEs activity is in the 
liver. For all three formulations, CPT showed the highest exposure in liver.  Because the 
nanosuspension particles will be trapped by the RES cells and released slowly, and only 
the free CZ48 molecules can be biotransformed to CPT. As a result, the CPT from 
nanosuspension also yielded a significantly longer β half-life in different organs 
compared to those from cosolvent. CZ48 nanosuspensions showed a much higher 
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spleen exposure, which may be a concern of potential off-target accumulation and 
toxicity. 
5.6.4. Organ Distribution of CZ48 Cosolvent and Nanosuspensions 
(NS-S, and NS-L) in Mice 
Similar as in rats, CZ48 nanosuspensions of two different sizes (NS-S and NS-L) 
exhibited distinct biodistribution patterns from that of cosolvent in mice. CZ48 from 
cosolvent was distributed evenly in all organs. Rapid decline of the total drug 
concentration in all organs, which can be characterized by a one-compartment model, 
indicated a fast elimination of CZ48 from these organs. 
CZ48 nanosuspension had the highest CZ48 exposure in liver, followed by spleen and 
lung, higher than in other organs. The high drug exposure in liver, spleen and lung from 
CZ48 nanosuspensions suggested the RES uptake of nanosuspensions, which was the 
same as in rats. Only the exposure of CZ48 in lung from NS-S showed a 3 times higher 
than that from NS-L which may be due to the extremely long half-life, 38.21 h and 3.07 h 
for NS-S and NS-L, respectively. And the prolonged half-life in lung could provide 
potential merits for lung cancer treatment. No significant difference was observed in 
other organs between NS-S and NS-L. 
CPT from all these three formulations also showed the highest exposure in liver.  
However, the CPT from nanosuspensions had longer β half-lives in different organs 
compared to those from cosolvent.  
 200 
 
All these properties may offer potential merits for CZ48 chemotherapy. Briefly, 
nanosuspensions after i.v. administration appeares to be a practical approach to 
introduce sustained levels of poorly soluble compounds over a period of hours, 
especially NS-S. It may the drug more effective or more tolerable by modifying and 
improving the drug performance, such as increasing the duration action and the reduced 
frequency of dosing (Wang Y et al., 2010). 
5.6.5. Proof of Concept Efficacy of NS-S in Lung Cancer Tumor 
Bearing Mice Model 
The present studies demonstrated that our nanosuspension formulation had 
substaintially lower toxicity than the cosolvent. Four times tail vein injection of cosolvent 
made severe tissue damage, but nanosuspension injection did not result in any damage. 
In addition, the blood was taken after the animal was sacrificed. Much darker and thicker 
blood was observed by cosolvent administration compared to no treatment goup and 
nanosuspension groups. Because of the low solubility of CZ48, the highest tolerate dose 
of CZ48 cosolvent was 5 mg/kg. Any increase of the cosolvent concentration will cause 
the animal death immediately due to the significant drug precipitation in the blood 
circulation. However, the dose of nanosuspension can be given up to 25 mg/kg due to 
the toxicity of the drug.  
Cosolvent and NS-S-L at the same dose level (5 mg/kg) did not exhibit significant 
efficacy over the control/reference groups. For most of the chemotherapy agents, there 
is a therapeutic window.  The phenomenon of lack of efficacy was not well understood, 
 201 
 
but might be due to the dose level could not reach the minimum therapeutic 
concentration, or it failed to keep the therapeutic concentration for a long enough 
duration.  
Wherevas, the treatment with NS-S-M yielded significant tumor growth suppression and 
prolonged animal median survival duration, compared to control groups. The significant 
onset tumor suppression was observed 3 days after the first dose given. This dose is the 
same as the pharmacokinetic study, which resulted in sustained circulation of CZ48 and 
CPT for more than 24 hours circulation in rodent animals. In this way, the significant 
efficacy may be attributable in part to the favorable pharmacokinetics of systemically 
delivery drugs, as well as to the inherent permeability by the tumor cells (Zou YJ et al., 
2004).   
For high dose group of CZ48 nanosuspension administration, it showed the highest 
tumor suppression, but after the first dose, two out of ten animals died. The death might 
be due to the toxicity of the high amount of CZ48. The dose was reduced from 50 mg/kg 
to 40 mg/kg twice weekly at the fourth dose, but still resulted in animal death (2 out of 7). 
Subsequently, the regimen was changed from 40 mg/kg twice weekly to once weekly. 
The significant tumor suppression could be investigated, but the toxicity caused 5 
animals death. These results with the high dose group suggested that CZ48 
nanosuspension could not be given more than 40 mg/kg at each time.  
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There was no significant body weight loss in any of these groups. Our promising results 
suggest that a therapeutic approach that uses nanosuspension delivery of this novel 
agent, CZ48, may warrant a further development.  
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Chapter 6 Summary  
6.1. Formulation of CZ48 Nanosuspensions 
The media milling technique was used in nanosuspension preparation where the solid 
drug particles were sheared between the sliding surfaces of the moving glass beads. T-
80 and F-108 were added as steric stabilizers to overcome the attractive interactions 
between the nanoparticles. A narrow particle size distribution was achieved by using a 
mixture of glass beads with various sizes were used instead of single-sized glass beads.  
6.2. Central Composite Design (CCD) 
Three processing critical variables, CZ48 concentration, F-108/CZ48 ratio and T-
80/CZ48 ratio, in the preparation method were identified and optimized by a scientifically 
and systematically efficient CCD design. The result of this mathematical analysis 
showed that CZ48 concentration and F-108/CZ48 ratio were the crucial parameters for 
the particle size of the nanosuspension prepared by media milling method; however, 
none of the factors investigated in this study had a significant quadratic relationship with 
the achieved zeta potential. Therefore, the statistical experimental methodology has 
clearly shown its usefulness in the optimization process and our study also serves as the 
groundwork for the understanding of nanosuspension formulation.  
Based on the CCD results, NS-S (200 nm) and NS-L (600 nm) were developed for 
further in vivo pharmacokinetic and efficacy studies that were successfully proved the 
hypothesis of the project.  
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6.3. HPLC Assay 
A previously developed HPLC method was modified and employed in quantifying CZ48 
and CPT concentrations from in vitro and in vivo studies. The assay was highly sensitive, 
reproducible and efficient. Plasma and organic precipitation yielded CZ48 and CPT 
recovery of 96%. The lower limit of quantification (LLOQ) was 0.78 ng/ml for CZ48 and 
0.55 ng/ml for CPT, improved from the previous LLOQ of the assay, 10 ng/ml for CZ48 
and 5 ng/ml for CPT, respectively. 
6.4. In-vitro Release of CZ48 from Cosolvent and Two 
Nanosuspensions (NS-S and NS-L) 
The release profiles of the nanosuspensions in PBS and human plasma had similar 
pattern except for a lower release rate and smaller extent in plasma. Cosolvent 
formulation had the fastest release rate and the highest release extent than those of 
nanosuspension groups in PBS and plasma. The small particle NS-S (200 nm) had a 
faster release rate than that of NS-L (600 nm) group in PBS. However, they did not show 
significant difference in plasma. By comparing the release in PBS to plasma, there was a 
reduction in the rate and extent of release in plasma due to the high binding of CZ48 to 
plasma proteins. The release profiles differences might result in different 
pharmacokinetic characteristics of CZ48. The release profiles were best described by 
the 1st -order kinetic equation in both release media.  
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6.5. Plasma Pharmacokinetics of CZ48 Cosolvent and 
Nanosuspensions (NS-S, and NS-L) in Rats 
The rat plasma profile of CZ48 cosolvent was used as a reference for the profiles from 
the nanosuspensions. The plasma concentration-time profiles of CZ48 from cosolvent 
followed a one-compartment kinetics. However, the plasma concentration-time profiles 
of CZ48 from NS-S and NS-L followed a three-compartment model. The AUC of CZ48 
from NS-S and cosolvent was comparable, but significantly higher than that from NS-L. 
The half-life of CZ48 from NS-S was the longest, which was about 4 times and 60 times 
of those from NS-L and cosolvent, respectively.  
The plasma concentration-time profiles of CPT from cosolvent followed a one-
compartment model. However, the plasma concentration-time profiles of CPT from NS-S 
followed a three-compartment model, and that from NS-L followed a one-compartment 
model. For NS-L, no distribution phase was observed, which might be due to the fact 
that the distribution kinetics of CPT was faster than that of the biotransformation. The 
AUC and half-life of CPT from NS-S was the highest followed by those from NS-L, and 
cosolvent. These properties might offer merits for the clinical application of CZ48.  
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6.6. Organ Distribution of CZ48 and Metabolite, CPT, from 
Cosolvent and Nanosuspensions (NS-S, and NS-L) in Rats 
(n=4) 
Being a particulate system, the nanosuspensions have a higher RES uptake of CZ48 as 
compared to that of the reference cosolvent. There is no significant improvement on the 
CPT exposure. However, the elimination half-lives of CZ48 and CPT from the different 
organs after nanosuspension dosing ranged from 1.39 h to 16.50 h, substantially 
prolonged by 2 ~ 48 times from those of cosolvent.  
6.7. Plasma Pharmacokinetics of CZ48 Cosolvent and 
Nanosuspensions (NS-S, and NS-L) in Mice (n=4) 
The profiles of CZ48 and CPT from NS-S and NS-L are similar where the initial phase 
has a rapid decline followed by a slower phase of elimination. However, the profile of 
cosolvent showed rapid clearances of CZ48 and CPT. The relative systemic exposure of 
CZ48 from both nanosuspensions were comparable to that from cosolvent. However, the 
exposure of CPT from NS-S and NS-L were 2.39 times and 1.31 times higher than that 
from the cosolvent. The elimination half-lives of CZ48 and CPT from nanosuspensions 
were prolonged more than 8 times compared to that from cosolvent.  
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6.8. Organ Distribution of CZ48 and Metabolite, CPT, from 
Cosolvent and Nanosuspensions (NS-S, and NS-L) in Mice 
(n=4) 
Being a particulate system, the nanosuspensions have a higher RES uptake of CZ48 as 
compared to that of the reference cosolvent. Similar to the result in rats, there is no 
significant improvement on the CPT exposure. However, the elimination half-lives of 
CZ48 and CPT from the different organs after nanosuspension dosing were prolonged 3 
to 10 times of those from cosolvent. 
6.9. NS-S Efficacy Study 
The treatment with NS-S-M at 25 mg/kg yielded significant tumor growth suppression 
and prolonged animal survival with an early onsite after 3 days of the first dose, 
compared to control groups. The tolerable dose of CZ48 nanosuspension was 
substantially increased by 5 times from 5 mg/kg to 25 mg/kg, compare that of cosolvent. 
The same dose level with cosolvent at 5 mg/kg did not show any advantage. Our 
promising results suggest that an optimal therapeutic regimen that uses nanosuspension 
delivery of this novel agent, CZ48, may warrant a further development.  
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